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INTRODUCTION
Mycotoxins are structurally diverse secondary metabolites of fungi that are pro
duced when fungal pathogens infect human or animal tissues; mytotoxins may also be

ingested with fungus contaminated food. The clinical syndromes caused by fungal toxins

have been extensively characterized and range from acute to chronic diseases with mild
symptoms to fatal outcomes. Some mycotoxins, at levels that do not cause overt clinical
mycotoxicosis, suppress immune functions and may decrease resistance to infectious

disease. The sensitivity of the immune system to mycotoxin-induced immunosuppression
arises from the vulnerability of the cells that participate in immune mediated activities and

regulate the complex communication network between cellular and humoral components.
Although the cellular-molecular basis for many of the specific immunosuppressive effects
of mycotoxins is unclear, inhibition of DNA, RNA and protein synthesis by means of
various mechanisms appears to be directly or indirectly responsible for the immunosup
pressive action of many mycotoxins (Cusumano, et al., 1996; Thuvander et al., 1996).

Gliotoxin (GT) is one such fungal secondary metabolite that reduces host resis
tance to Aspergillus and Candida infections in humans, and functions as an immuno

modulator. It has been proposed that the effect of GT on the immune system may serve to

make certain fungal infections more chronic. In addition to its function as a virulence

factor, it may have a useful role as an immunologic reagent. Although GT has been used
to inhibit transplantation rejection (Mullbacher, 1984; Mullbacher, et al., 1986; Waring and
Mullbacher, 1992), the research reported in this dissertation is the first study in which GT
is used to prevent autoimmune insulin dependent diabetes mellitus (EDDM).
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Insulin Dependent Diabetes Mellitus
Autoimmune disorders
Autoimmune diseases are disorders caused by inflammation and destruction of
tissues by the body’s own immune actions. Autoimmune diseases develop on a susceptible
background involving multiple genes (Davies, 1994), some of which are associated with

immune regulation and some of which control target-organ functions (Kennedy, German

and, Rutter, 1995; Bennett, et al., 1995). Although the mechanism is not clear and may
differ with the specific autoimmune disease, several hypotheses have been proposed to
explain the autoimmune diseases (Theofilopoulos, 1995). The poorly displayed “cryptic

self’ determinants allow autoreactive lymphocytes to escape from negative selection.

Faulty antigen presentation stimulates autoimmunity by presenting self antigens. Molecular

mimicry has been reported to result in cross reaction between self and foreign peptides.
Autoimmunity may also arise as a result of immune responses against modified self

determinants. Errors in central and peripheral tolerance at the T and B lymphocyte level

are also implicated as causes for autoimmunity. Polyclonal B and/or T cell activation by
superantigens has been considered a contributing or initiating mechanism in autoimmunity,

particularly in systemic autoimmune diseases.

Although these various sources of

autoimmunity may account for some cases, most investigators consider immunoregulatory

disturbances as a primary cause of autoimmune diseases. Some T lymphocyte subsets,
such as CD4+, CD8’ and RT6+ T cells, are involved in the regulatory process. A changing

balance between Thl and Th2 lymphocytes provides a good example of autoimmune

induction through immunoregulatory disturbance.

2

In humans, autoimmune reactions might reflect immune defects such as occur in

lymphoproliferative disorders (Brouet, Mariette and Sligmann, 1994), in patients carrying
null complement alleles

(Batchelor, et al., 1987), Fas mutations (Rieux-Laucat, et al.,

1995; Fisher, et al., 1995), or in chronic graft-versus-host disease (Goldman, Druet and

Gleichmann, 1991).

Other uncommon situations include autoimmune paraneoplastic

syndromes (Lennon, et al., 1995) and pregnancy (Kelly, et al., 1988), in which tumor cells

and the placenta, respectively, express autoantigens shared by a peripheral tissue.
Autoimmunity may also be induced by infectious agents (Kotb, 1995) or drugs (Goldman,

Druet and Gleichmann, 1991) that modify the tissue and stimulate the immune system.
There are two categories of autoimmune diseases, organ-specific and systemic

autoimmunity. The autoantibodies of organ-specific autoimmune disease are associated
with components of the specific organ so that a lesion or target tissue destruction is

localized.

The organ-specific diseases involve the thyroid (Hashimoto’s thyroiditis,

primary myxoedema and thyrotoxicosis), the stomach (pernicious anaemia), the adrenal

(Addison’s disease), or the pancreas (IDDM). The organ-specific diseases are caused by

humoral immunological responses against self-antigens for which T-cell tolerance is

normally not established.
The immune responses of systemic autoimmune diseases are directed against distributed antigens.

Although systemic autoimmune damage is widely dispersed, certain

organs or tissues may be particularly affected by systemic autoimmunity. For example, the

systemic autoimmune diseases include dermatomyositis of muscle, systemic lupus

erythematosus (SLE) of joint, skin and kidney, scleroderma of skin and kidney, and
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rheumatoid arthritis of joints. The causes of systemic autoimmune diseases are less clear

than the tissue-specific autoimmune diseases. Gene defects leading to inadequate T cell
tolerance may explain some cases of systemic autoimmunity. Defective of apoptosis, for
example, is the mechanism in murine Ipr/gld SLE models (Theofilopoulos, 1995).

Target tissue of autoimmune diseases
The anatomical and physiological organization of target tissues influences many

aspects of autoimmune diseases and their respective clinical manifestations. These include
the homing of inflammatory cells and lymphocytes, antigen presentation, the level of

autoantigen expression or expression of neoantigens, and the spread of the autoimmune
reaction. Moreover, several features point to antigen-driven responses in autoimmunity,

including the use of recurrent idiotypes and V genes, the high rate of replacement
mutations in complementarity-determining regions (CDRs) of the variable domains of

autoantibodies (Radic and Weigert, 1994), and the clustering of autoantibodies directed
against antigens associated with subcellular particles in a particular disease (Tan, 1991).
Genetic susceptibility conferred by genes encoding autoantigens (e.g., myelin basic

protein, acetylcholine and thyrotropin receptor, and insulin) has also been reported in
autoimmune diseases (Garchon, et al., 1993; Boylan, et al., 1990; Tienari, et al., 1992;
Bell, Horita and Karam, 1984; Julier, et al., 1991). Additional evidence for the role of

target cells includes demonstration of early target organ dysfunction in autoimmune
conditions (Homo-Delarcher, Boitard and Boitard, 1996).

The autoimmune antibodies

appear and are consistently detected beginning at a very early stage of autoimmune disease
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development. The autoimmune antibodies, while probably not being responsible for the

majority of autoimmune damage, serve to make early diagnosis possible so that

intervention strategies can be applied before onset of significant autoimmune damage.

Insulin dependent diabetes mellitus as an autoimmune disease

Diabetes mellitus comprises an etiologically and clinically heterogeneous group of

hyperglycemic disorders.

Hyperglycemia is the consequence of a relative or absolute

deficiency of insulin in the presence of a relative or absolute excess of glucagon. When
the insulin deficiency is extreme, these hormonal abnormalities are responsible for the

tendency to develop ketoacidosis.

Diabetes is associated with a set of late onset

complications involving the eyes, kidneys, nerves, and blood vessels. Diabetes is fatal in
the absence of insulin treatment which must be continued for life (Wilson and Foster,

1992).

The term "type I diabetes mellitus" is used to specify diabetes secondary to

autoimmune destruction of insulin producing pancreatic islet B-cells. This disease is also

known as insulin-dependent diabetes mellitus (IDDM) or juvenile onset diabetes since
patients survive only with exogenous insulin treatments and the disease usually develops at

an early age. IDDM is a disorder of carbohydrate metabolism in which glucose is not
oxidized to produce energy due to a lack of insulin. In contrast, type II diabetes is due to
peripheral resistance to insulin. IDDM develops in about three per 1,000 persons in the
general population and in about three per 100 first-degree relatives of patients with type I

diabetes (Eisenbarth, 1989).

As indicated in Table 1, human IDDM is known to be

associated with a recessive diabetogenic gene in the major histocompatibility complex
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Table 1. Susceptibility loci and candidate genes for autoimmune diabetes
(Theofolopoulos, 1995).

Chromosomal location

Locus designation

Candidate genes

Bcgl/Lch/Ity
IL-2
Fcgrl, Csfin, Cd53

7
9
11
14
17

Idd-5
Idd-3
Idd-10
Idd-9
Idd-6
Idd-7
Idd-2
Idd-4
Idd-8
Idd-1

BB rat
4
20

Iddml/Lyp
Iddm2

MHC

IDDM1
IDDM5

GAD1
MHC
SOD2

NOD mouse
1
3
3

4
6

Human IDDM
2q
6p21
6q
8p
8q
lOq
1 lql3
1 lp!5
18q

Bphs

Nosi

MHC

GAD2

IDDM4
DDDM2
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(MHC) on chromosome 6, although expression of a particular HLA gene is not by itself

sufficient to cause autoimmune disease (Theofilopoulos, 1995). Both class I and class II
MHC molecules seem to have a role in the immune reactions that characterize

development of IDDM, although the mechanism is unknown.
The pancreatic islets of Langerhans are the targets of the autoimmune reaction that

leads to IDDM. This highly selective destruction of 60-70% of the insulin-secreting p

cells, the major endocrine component of the islet (Bach, 1994; Leahy, Bonner-Weir and
Weir, 1988) leads to disease.

Insulitis, the histological hallmark of IDDM, varies in

severity from one islet to another in an individual pancreas. The disease in humans follows

a highly chronic course and clinical diabetes is only manifest when a majority of P cells has

been destroyed.
Bold experimental procedures cannot be undertaken in humans, making the avail
ability of animal models of IDDM critical for diabetes research. Animal models include
rats and mice.

Rats seam relatively tolerant of pancreatic destruction, remaining

normoglycemic following 60% pancreatectomy (Wilkin and Armitage, 1985).

As in

humans, a very substantial loss of pancreatic function is required for clinical diabetes. In

the NOD mouse model of IDDM, insulitis precedes hyperglycemia by weeks or months; in
humans, the detection of autoantibodies precedes diabetes onset by several years.
Evidence of autoimmunity in IDDM includes the detection of both autoantibodies and T
cells specific to islet autoantigens, as well as an association with a restricted set of MHC

class II alleles.
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Autoantigens

IDDM has been considered as an autoimmune disease because of the discovery of

islet cell autoantibodies (ICAs) in patients with a recent onset of the disease (Beakkeskov,
et al., 1982). Several autoantigens in IDDM that are recognized by autoantibodies have
been studied for almost two decades (Table 2). The most commonly mentioned autoanti

gen in IDDM is a 64 kDa P-cell-specific glutamic acid decarboxylase (GAD). Circulating

autoantibodies to GAD antigen are often detectable by immunoprecipitation of radiolabeled islet lysates with IDDM sera (Michelsen et al., 1991). GAD catalyzes the conver-

sion of glutamic acid to y-aminobutyric acid, which is the major membrane-stabilizing
neurotransmitter of the central nervous system. Two forms of GAD, known as GAD65

and GAD67, are encoded by separate genes (Bu, et al., 1992; Robin, et al., 1994). An
islet-surface autoantigen, ICA-512, has been described recently, which is a member of the
protein tyrosine phosphatase (PTP) family (Lan, et al., 1994), and another ICA antigen

has recently been identified and termed insulinoma antigen 2 (IA-2). The typical fragment
of IA-2 is 40 kDa and its derivative, IA-20, is 37 kDa. Insulin itself is also a P-cell-

specific autoantigen (Song, Li and Maclaren, 1996).

There are several other putative

candidate autoantigens in IDDM that remain under investigation (Table 2).

These

autoantigens may be starting points of IDDM pathogenesis or may simply be early signs of
IDDM.

GAD can be detected by autoantibody in immunoprecipitation reactions long

before clinical IDDM onset. The early detection of autoantibodies suggests that it may be
possible to use them as an early warning to trigger clinical immune intervention to block
the autoimmune process, or to use other therapeutic reagents to cure IDDM.
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Table 2: Autoantigens and candidate autoantigens in IDDM (Song, 1996)

Autoantigens

Research situations

GAD65
GAD67
Tyrosine phosphatases IA-2 and IA-2p
_____________ Insulin_____________
Insulin receptor
Carboxypeptidase H

Atoantigens in IDDM

Candidate autoantigens in IDDM

Peripherin
ICA-reactive gangliosides
Heat shock protein 65 (Hsp65)
ICA-69
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Animal Models
General characteristics of DP/BB rats
For the study of IDDM, several useful animal models have been developed. These

include the spontaneously diabetic BioBreeding (BB) rat and the NOD mouse models.
Since this research used the BB rat model, most of the review of animal models will be

devoted to BB rats.

Characteristics of diabetes in the BB rat closely parallel those

observed in human IDDM. The genetic, immunological and environmental factors that

predispose to the disease can be investigated under controlled conditions. There are two
inbred lines in this model system, diabetes prone (DP) and diabetes resistant (DR) BB rats,

which were developed from the Wistar rat line. DP/BB rats were used exclusively in this

research. DP/BB rats develop diabetes abruptly at 60-120 days of age with an incidence
of about 86%.

This condition is characterized by sudden weight loss, hyperglycemia,

hypoinsulinemia, glycosuria and ketonuria. Histologic insulitis (lymphocyte infiltration of

pancreatic islets) is observed at the onset of spontaneous diabetes mellitus in DP/BB rats.

A venular defect characterized by lymphocyte adherence and loss of endothelial integrity

in the pancreas has been described in both DP/BB and DR/BB rats. Autoimmune thy

roiditis, an increased susceptibility to pulmonary infections, and other abnormalities have
also been reported in DP/BB rats (Crisa, Mordes and Rossini, 1992; Guberski, 1994).
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Cellular and molecular aspects of DP/BB rats

Unlike human IDDM, severe lymphopenia is a key feature in DP/BB rats, with a
marked decrease of CD4+ and CD8+ T cell subtypes (Prud’homme et al., 1988; Jackson,

1983; Woda, et al., 1986), and relative increases of CD5* B cells and NK cells (Woda and
Biron, 1986). RT6+ cells (a subset of mature T lymphocytes described in detail below) are
virtually undetectable in the spontaneously diabetic DP/BB rat.

In contrast, normal

numbers of T cells expressing the RT6 alloantigen are present in the periphery of DR/BB
and other normal rat strains (Table 3).

Susceptibility loci in the diabetes prone BioBreeding (DP/BB) rat have been
identified (Theofilopoulos, 1995).

A locus, iddm2, is linked to the rat MHC on

chromosome 20 and contributes to diabetes in a semidominant fashion. Unlike the NOD

mouse and human IDDM, the DP/BB rat is characterized by a recessively inherited severe
T-cell lymphopenia due to iddml located on chromosome 4 (Table 1).

Environmental factors

In addition to genetic predisposition, environmental factors are involved in the
pathogenesis of EDDM in humans as well as experimental animals. Certain viruses such as

rubella, coxsackievirus, and cytomegalovirus have been reported to play a role in human
diabetes pathogenesis. Parvovirus and Kilham rat virus, are considered as triggers of

IDDM in BB rats.

In contrast, lymphocytic choriomeningitis (LCM) virus actually

prevents IDDM in NOD mice and BB rats. Mouse hepatitis virus, encephalomyocarditis

virus, and lactate dehydrogenase elevating viruses have been reported to prevent IDDM in
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Table 3. Clinical and immunological iharacteristics of diabetes-prone and diabetes
resistant BB/Wor rats (Crisa, et al., 1992)

Cumulative frequency of
diabetes
Age at onset
Insulitis
Diabetics
Nondiabetics
Thyroiditis

Peripheral lymphocytes
Lymphocyte subsets
0X19 (CD5)
W3/25 (CD4)
0X8 (CD8)
0X22, 0X32 (CD45R)
RT6
RT6" intraepithelial
lymphocytes
NK cell activity
In vitro response of T
cells to mitogen

Diabetes-prone

Diabetes-resistant

86%

< 1%

> 85% of cases
between 55 and
120 days of age

usually between 50
and 60 days of
age

yes
50%
5-100% depending on
subline
lymphopenic

yes
13%
11%

low
low
low
low
absent or very low
present

normal
normal
normal
normal
normal
present

increased
depressed

normal
normal
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nonlymphopenic

NOD mice. Some bacterial and fungal extracts have been reported to exert effects against
IDDM in NOD mice and BB rats (Rabinovitch, 1994). Laboratory diets containing plant
products, such as gluten flour and soybean meal, can enhance diabetes pathogenesis while
semisynthetic diets rich in L-amino acids and hydrolyzed casein diets reduce the incidence

and delay the onset of diabetes (Crisa, Mordes and Rossini, 1992; Guberski, 1994).

Vitamin A intake is also involved in diabetes development.

Retinol deficient diets

decreased diabetes and insulitis in DP/BB rats and retinoic acid partly substituted for

retinol in the development of insulitis. (Driscoll, et al., 1996)

Modification of Disease by Gliotoxin
Chemistry of gliotoxin
GT is a secondary fungal metabolite originally isolated in 1932 from a strain of
Trichoderma lignosum.

GT (Figure 1) was the first described member of the

epipolythiodioxopiperazine (ETP) family (Figure 2) which comprises more than 50
separate compounds produced by the higher filamentous fungi. GT has antimicrobial
activity, especially against gram-positive bacteria, and also inhibits the multiplication of

some RNA viruses. Dose-dependent toxicity of ETP compounds against a variety of
mammalian cells has been reported, although susceptibility varies with cell type. These

diverse biological activities derive from a reactive disulfide bridge on the piperazine ring
that may form mixed disulfides with sulfhydryl or disulfide groups on critical cellular pro
teins. This causes oxidation or reduction of cellular components, or may trigger surface

13

Figure 1.

Molecular structure of gliotoxin (GT).

GT is a fungal secondary

metabolite and a member of the epipolythiodioxopiperazine (ETP) family. The disulfide
group of GT which bridges the piperazine ringmay bind to disulfide groups on target
proteins to trigger cell surface receptors or participate in oxidation-reduction cycling.

14

o
x

x

s
s

N------CH3
\

X

OH
CH2OH

15

Figure 2.

General structure of epipolythiodioxopiperazines (EPT).

The

diketopiperazine ring is flat in crystal structure, interconverting to a boat conformation in

solution.

The presence of the disulfide linkage locks the molecule into one of the

conformations. “R” indicates substituent groups and “n” is the number of sulfur atoms

which range from 1 to 4.
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receptors by cross-linking them through mixed disulfide linkages (Waring, Eichner and
Mullbacher, 1988).

Biological effects of gliotoxin
GT, produced by fungi in the vertebrate host, could play a significant role in the

pathogenesis and mortality of aspergillosis. The potential importance of GT is indicated
by the observation that it is synthesized by many different fungi, including strains of

Candida (Shah and Larsen, 1991) which, along with Aspergillus, are the two most

prevalent pathogenic fungi.
A saprophytic, thermophilic fungus, Aspergillus fumigatus, which produces GT in
culture (Mullbacher, et al, 1985), is an opportunistic pathogen in humans and animals and

is responsible for potentially fatal disseminated aspergillosis in immunocompromised
individuals. Individuals exposed to Aspergillus fumigatus can also display aspergilloma or
“fungus ball” which is a saprophytic growth in a damaged lung. Mullbacher and Eichner

(1984) have proposed that in situ GT production by the fungus Aspergillus fumigatus
enhances the progression of lung disease.

Immunological effects of gliotoxin
GT has been described as an immunomodulator and possesses in vitro immunosup
pressive activity. This compound inhibits phagocytosis by activated peritoneal macropha

ges (Waring, et al., 1990) and also inhibits mitogen-induced T cell proliferation and the
activation of cytolytic T lymphocytes, by partially inhibiting lymphokine release
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(Mullbacher, 1984; Mullbacher, et al., 1986). The ex vivo treatment of bone marrow with

GT prevents graft-versus-host disease in allogeneic bone marrow transplantation by selec
tively depleting the bone marrow of mature lymphocytes (Waring and Mullbacher, 1992).

The immunomodulating effects of GT have been demonstrated in vitro (Waring,

1990; Waring, et al., 1988). GT has increased toxicity in irradiated mice, it delays the
recovery of the immune system in vivo after immunosuppression by sublethal irradiation,

and it induces apoptosis in the cells of lymphoid organs (Sutton, et al., 1994).

Immunology of Insulin Dependent Diabetes Mellitus

Pathogenesis
The immunologic events in diabetogenesis are summarized in Figure 3. The initial

event in the immune response leading to IDDM is the uptake and processing of self
antigen by such antigen presenting cells (APC) as macrophages or dendritic cells.

In

association with surface MHC class I or class II molecules, APC present processed

antigens to T helper (Th) cells. CD4* or CD8+ Th cells with specific receptors recognize
and bind to these class II or class I MHC and antigen complexes respectively. Th cell

binding to the antigen-MHC complexes leads to Th cell activation and cytokine release.
Cytokines, such as IL-2, activate toxic T cells, toxic macrophages, natural killers (NK)
and other effectors, which contribute to the destruction of pancreatic islet B-cells, resulting

in IDDM (Rabinovitch,1993).
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Figure 3. Induction of EDDM. This scheme presents an abbreviated model of possible

immunologic interactions between pancreatic antigen presenting cells (macrophages,
dendritic cells and B cells), regulatory lymphocytes (Th and Tc cells), effector cells (NK

and Tc) and islet B-cells leading to destruction of the pancreatic cells

In this model, p

cell antigen is presented by APC in association with MHC II complex. This stimulates

subsets of regulatory cells (helper T cells) which use cytokine secretion to activate effector
cells (NK cells and cytotoxic T cells).

The activated effectors attack insulin secreting

pancreatic 3 cells. When most of the pancreatic 3 cells are destroyed, the host becomes
diabetic.
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Islet B-cells

CD4+ lymphocytes
CD4 and CD8 are T cell surface glycoproteins that are expressed on subsets of
mature T cells with distinct patterns of MHC restriction.

CD4 and CD8 serve as

accessory molecules by facilitating interactions of T cells with APCs or cytotoxic T

lymphocytes (CTL) with target cells.

Both molecules are members of the Ig gene

superfamily, but they are no more related to one another than to other members of the
family. Approximately 65% of peripheral aP-positive T cells express CD4 and 35%
express CD8 (Abbas, Lichtman and Pober, 1991).
CD4 is a transmembrane glycoprotein, approximately 55 kD in size, which is ex

pressed as a monomer on the surface of both peripheral T cells and thymocytes. CD4 has
an extracellular region with four Ig V-like domains, a hydrophobic transmembrane region

and a highly basic cytoplasmic tail. CD4 serves as a cell-cell adhesion molecule. The

binding of CD4 to class II MHC molecules stabilizes the interaction of T cells with APCs.
The CD4 molecule may transduce signals or facilitate TCR:CD3 mediated signal

transduction (Abbas, Lichtman and Pober, 1991). The relationship between CD4’ T cells

and onset of IDDM is currently not very clear. An investigation of NOD mice indicated

that CD4’ T cells are not involved in the induction of IDDM, since CD8* T cells alone
induced IDDM (Wong, et al., 1996). CD4+CD8' thymocytes are a highly potent source of
cells that have the ability to control autoimmune diabetes in rats. CD45Rciow CD4* T

lymphocytes are considered as protective cells in IDDM prevention. Some investigators

believe this cell subset to be synonymous with Th2 cells.
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CD8+ lymphocytes
Although CD8 is a transmembrane glycoprotein, the structure of the CD8 mole
cule varies among species and among T cells at different stages of maturity. It consists of
either a homodimer of CD8oc or a complex composed of CD8a and CD8p. Both CD8ct

and CD8P are members of the Ig superfamily with N-terminal extracellular Ig V-like

domains, connecting peptides, a hydrophobic transmembrane region, and a highly basic
cytoplasmic tail (Abbas, Lichtman and Pober, 1991). The relationship of CD8+ T cells to

fDDM and other autoimmune disorders has been discussed in a number of recent studies.
Di-Cesare et al (1994) found that soluble CD8 levels were above the normal range in some

newly diagnosed IDDM patients. Elevated levels of soluble CD8 at a time near diabetes
onset may indicate that the activation of CD8' T cells is responsible for the autoimmune

beta cell destruction. Using the method of depleting certain T cell subsets, Forwell and
Mason (1993) demonstrated that the CD8+ T cells were essential for the development of

diabetes but not insulitis. Other investigators indicated that in development of diabetes in
NOD mice, CD8+ T cells function as an initiator to recruit CD4+ T cells to islets as well as

a final effector (Amano, et al, 1995). CD8+ T cell subsets have been found important in

other autoimmune diseases. Tada, et al. (1996) suggested that CD8+ T cells play a role in
the initiation and the recovery phase of collagen-induced arthritis (CIA). CIA incidence in

CD8 -/- mice was significantly decreased compared with CD8 +/- mice. Interestingly,
CD8’ deficient mice were more susceptible to a second induction of arthritis after
remission of initial disease, pointing towards an immunoregulatory role for CD8* T cells.

23

RT6+ lymphocytes
As shown in Table 4, RT6 is a T cell alloantigen that occurs in at least two forms,
RT6.1 and RT6.2. RT6 develops extrathymically and is expressed on about 50% of T

helper cells and on about 60% of cytotoxic T cells (Jiang, et al., 1990). Depletion of RT6‘

T cells in DR/BB rats can induce diabetes while transfusion of RT6+ T cells from DR/BB
rats into DP/BB rats prevents diabetes, proving that RT6* T cells play a critical role in the
pathogenesis of BB rat autoimmunity, perhaps by regulating autoimmune T cells (Woda et

al., 1991; Whalen, 1994).
RT6 is one component of a multi-subunit receptor complex. RT6 is associated
with src family tyrosine kinases and generates an activation signal (Rigby, et al., 1996). In

this model, RT6 interacts with at least five cytoplasmic proteins, including p56/c* and
p60/vn, mediated by an as yet unidentified linker molecule analogous to gp!30.

PKC

activation is able to modulate RT6 signaling. RT6 delivers an “accessory” signal that

increases expression of cytokine receptors and enhances the ability of these T-cells to
enter the cell cycle in response to growth factors like IL-2 and/or IL-4. The activation

signaling pathway involving RT6 could provide a control point for activation of an
antigen-engaged regulatory T-cell population, thereby modulating immune function (Table

4).

Natural killer cells
Natural killer (NK) cells are a subset of lymphocytes with prominent cytoplasmic
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Table 4. Characteristics of the RT6 rat T cell alloantigen
(Crisa, et al., 1992)

Marks 60-70% of peripheral T cells
Two genes, designated RT6a and RT6b, encode two surface
proteins, RT6.1 and RT6.2, respectively
RT6 is linked to the cell surface by a phosphatidylinositol
anchor
RT6.1 consists of a 24-26 kDa nonglycosylated peptide plus at
least five additional differentially glycosylated
polypeptides of 30-35 kDa
RT6.2 corresponds to a 24-26 kDa nonglycosylated polypeptide
RT6 maps to linkage group I on rat chromosome 1
RT6 is not expressed on thymic or bone marrow cells
>1/2 of CD4+ T cells are RT6"
>2/3 of CD8* T cells are RT6+
>1/3 of CD4+ CD45R+ T cells are also RT6+ (in the DR-BB rat)
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granules and are found in blood and lymphoid tissues, especially the spleen. NK cells are
viewed as CTLs that lack the specific T cell receptor (TCR) for antigen recognition.

Although the target specificity of NK cells is broader than that of CTLs, it is not random.
NK cells express CD2 and CD 16. As with CTLs, NK granule exocytosis and secretion of

a cell toxin are involved in killing by NK cells.

NK cells may be involved in some

autoimmune processes, such as graft-versus-host disease (GVHD) among bone marrow
transplant recipients (Abbas, Lichtman and Pober, 1991). For years, functions of NK cells

in IDDM pathogenesis have been discussed. Jiang et al (1994) found a relative abundance
of Tc and NK cells in the islets of acutely diabetic DP and RT6-depleted DR rats. They
also found the expression of cytolysin mRNA which encodes a cytolytic pore-forming

protein produced by both Tc and NK cells. They demonstrated that in the islets of acutely
diabetic DP rats and RT6-depleted DR rats, NK cells were more abundant than in normal

rats.

Contrary results have been obtained in another study. Shachner et al (1992) argued

that CTL cells played a role in pathogenesis of the disease and NK cells are not necessary
for autoimmune islet destruction.

Thl and Th2 lymphocytes
Thl and Th2 cell subsets are generally CD4+, but may be CD8\ Antigen-activated
Th cells aid in mediating both cellular and humoral (antibody) immune responses. At least

two distinct Th-cell types, Thl and Th2, have been described in humans, mice and rats

based on their distinct cytokine secretion patterns. Thl cells produce IL-2, TFNy, and
TNF-B (lymphotoxin), whereas Th2 cells produce IL-4, IL-5, and IL-10. Other cytokines,
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such as IL-3, GM-CSF and TNFa, are produced by both Thl and Th2 cell populations.
Thl and Th2 cell subsets, releasing distinct patterns of cytokines, lead to different T cell

actions (Rabinovitch, 1993; Paul and Seder, 1994).
Thl cells and their cytokine products mediate cellular immunity (delayed-type

hypersensitivity). IFNy and TNFB activate vascular endothelial cells to recruit circulating
leukocytes and activate cytotoxic macrophages to eliminate the antigen-bearing cells. IL2 and IFNy activate CTLs to kill target cells with MHC-associated antigen and activate
NK cells to kill target cells in an MHC-independent fashion. The production of cytokines

by Thl and Th2 cells are mutually inhibitory which creates a situation of dynamic balance
between these two cell classes. IFNy inhibits the production of Th2 cytokines while IL-4

and IL-10 inhibit production of Thl cytokines.

Cytokines secreted by Thl cells will

activate effector cells, including cytotoxic macrophages, cytotoxic T cells and NK cells,

and will be expected to promote EDDM. Meanwhile, cytokines of Th2 cells will inhibit
those effector cells and actually protect from autoimmune disease.

Immune regulation through apoptosis

Regulation of immune function occurs by various mechanisms including deletion of

certain cell types. The life and death of lymphocytes is tightly controlled by membrane
receptors that activate either proliferative or apoptotic (programmed cell death) processes.
Fas (also known as Apol or CD95) antigen, a 48 kDa surface protein, has been identified

as a key receptor involved in apoptotic death among lymphoid cells. Mutations in the
gene which encodes Fas are responsible for lymphoproliferative disorders and an
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•

associated lupus-like syndrome in Ipr and Ipr

C’R

mice. Defects in Fas-induced apoptosis

may lead to incomplete elimination of peripheral autoreactive cells in these mice. A recent
investigation found that patients with lymphoproliferative syndromes and autoimmune

disorders have a large deletion in the Fas gene and no detectable Fas expression (RieuxLaucat, et al., 1995).
Autoreactive T cells die by means of apoptosis during thymic development by a

negative selection process (Ogasawara, Suda and Nagata, 1995). In addition, autoreactive

mature T cells are also deleted in the periphery. Fas is expressed in activated mature T
cells, and Fas-mediated apoptosis occurs during the induction of peripheral tolerance

and/or in the antigen-stimulated suicide of mature T cells (Nagata, 1994). These findings

illustrate the crucial role of Fas in apoptosis and may provide a molecular basis for some
autoimmune diseases in humans.

IDDM Prevention by Immune Manipulation
Diabetes prevention

In recent decades, many therapeutic intervention strategies have been proposed
and studied for IDDM prevention. Most have involved experimental animals, but some
have been applied to human subjects. Several methods, summarized in Table 5, are known

to reduce IDDM in animals (Bowman, Leiter and Atkinson, 1994). Immunosuppressive
drugs, cyclosporin A (CsA) and FK-506, can effectively prevent or delay IDDM in BB
rats and NOD mice (Mori, et al., 1986; Miyagawa, et al., 1990).

Treatments that

compromise the effector functions or viability of either CD4+ or CD8+ T cell subsets can
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Table 5: Therapies that prevent diabetes in NOD mice
(Bowman, Leiter and Atkinson, 1994)
neonatal thymectomy
anti-lymphocyte serum
ant i-Thy-1
anti-CD3
anti CD4
anti CD8
cyclosporin
FK-506

T-cell functions:

Immunosuppression

anti-complement receptor
silica

Macrophage/APC
(antigen presenting
cell) function:

Pathogenic viruses:

Immunostimulation

cytokines or
cytokine inducers:

LDHV (Lactate dehydrogenase virus)
anti-MHC (major histocompatibility complex) class I
anti-MHC class II
blocking peptide for anti-MHC class II
anti-IFN-y (interferon y)

LCMV (lymphocytic choriomeningitis virus)
EMCV (encephalomyocarditis virus)
MHV (murine hepatitis virus)
IL-1 (interleukin-1)
TNF-a (tumor necrosis factor a)
IL-4
IFN-y
poly [icj
ConA (concanavalin A)
CFA (complete Freund’s adjuvant)
BCG (Bacille Calmette Guerin)
OK432
heat-shock protein 65

Others:

bone-marrow transplantation
intrathymic islet transplantation
oral insulin
dendritic cells from pancreatic node
neonatal tolbutamide treatment
immunization with insulin or insulin B chain

Tolerance induction

gonadectomy
prophylactic insulin treatment
diazoxide
elevated temperature
semi-purified diets

Manipulation of
hormonal/dietary milieu

Nicotinamide
superoxide dismutase-desferrioxamine
vitamin E
aminoguanidine

Anti-inflammatory
agents
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retard or circumvent diabetes (Maki, et al., 1992; Sempe, et al., 1991).
immunostimulation is also used in IDDM prevention.

Meanwhile,

Some viruses prevent IDDM in

experimental animals by means of stimulating cytokine production and other immune
responses. Therefore, it is not surprising that cytokine treatment and cytokine induction

are also useful methods in those animal studies.

Therapeutic protocols, such as oral

insulin administration (Atkinson, Maclaren and Luchetta, 1990), insulin vaccine to induce

tolerance (Williams, et al., 1993), and the injection of dendritic cells or splenocytes (ClareSalzler, et al., 1992), may induce regulatory tolerance or clonal anergy in T lymphocytes

reactive to islet antigens.

Recent studies indicated that intrathymic or intravenous

administration of recombinant GAD-65 results in acquisition of T cell tolerance to P-cell

autoantigen (Kaufman, et al 1993; Tisch, et al., 1993). Hormonal or dietary manipulation,

and anti-inflammatory agents are also reported as effective therapeutic interventions for
IDDM in BB rats and NOD mice. Because GT is an immunomodulator and immunosup
pressive factor, it may also have a role in IDDM prevention, as will be elaborated later.

Immune modulators
Drugs regulating apoptosis would also be anticipated to have therapeutic or

preventive value in autoimmune diseases if the induced apoptosis involved an appropriate
class of cells such as autoreactive lymphocytes or regulatory cells that would otherwise
promote cytotoxic reactions against pancreatic cells. CsA (Figure 4) and its analogue,

FK506 (marketed under the name, Tacrolinus or Prograff), are used in transplantation

medicine to increase survival rates of kidney and other organ transplantations (Borel,
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Figure 4. Structure of cyclosporin A (CsA).

This immune suppressive compound is

used clinically in transplantation medicine. The compound is a macrocyclic fungal product

and in comparison to GT (see Figure 1) shows a vastly different chemical structure. It has
no bridge moieties as GT does. CsA has been used to block autoimmunity in experimental
animal models, although it displays significant renal toxicity which limits its long term use.
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CsA and FK506 inhibit T cell response to the allograft (Thomson, 1992), by

inhibiting the expression of lymphokine genes, including IL-2, IL-3, IL-4, GM-CSF,

TNFoc, and IFNy. Cytokine inhibition results from interference with the synthesis or trans
port of several nuclear proteins into the nucleus, or is due to inhibition of their functional

activation (Schreiber and Crabtree, 1992). CsA blocks apoptosis by inhibiting the DNA

binding activity of transcription factors (Erlanger, 1992; Shi, Sahai and Green, 1989).
Because of its immunosuppressive effects, CsA has also been proposed for use in EDDM
and other autoimmune diseases. In a sense, the promotion of allograft survival may be

conceptually parallel to pancreas survival in the diabetic host. However, the side effects of
CsA, primarily nephrotoxicity, are the greatest limitation to extensive use, particularly in

autoimmune diseases where prolonged administration may be required.

It should be

remembered that one of the adverse effects of diabetes itself is renal compromise and
ultimately renal failure. Thus, it is ironic that CsA treatment could actually cause some of

the same symptoms that the disease (EDDM) would otherwise cause.

Cyclosporin A, FK506, reticuloendothelial blockade, anti-NK cell antibody, and
other treatments have been tried in DP/BB rats.

These treatments are not clinically

satisfactory because of significant toxicity or other side effects.

These immunologic

reagents are able to prevent diabetes in DP/BB rats, indicating that the autoimmune

reaction may be interdicted at several different points, including the generation or
activation of autoreactive lymphocytes, the restoration or activation of regulatory cells,

the inhibition of effector cells which participate in destruction of the pancreatic B-cells,
and unregulated suppression or release of cytokines.
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These points of autoimmune

interdiction provide a conceptual approach with which to study the potential beneficial
effects of GT in diabetogenesis among disease prone rats.

A possible role for gliotoxin in autoimmunity and diabetes
As noted above, IDDM is a complex autoimmune disease that may ultimately be

treatable by immunologic interventions that alter the function of autoreactive lymphocytes,

augment the function of protective regulatory cells or prevent the toxic action of such

effector cells as macrophages and NK cells that destroy pancreatic B-cells (Figure 3). CsA
has value as an immunosuppressive therapy, but some severe side effects limit its clinical

use. GT is very different chemically from CsA and may be exploited either therapeutically

or as an immunologic reagent to prevent or treat type I diabetes and other autoimmune

diseases. The work described here will provide a better understanding of the mechanism
involved in diabetes prevention by GT and reveal whether GT or one of its congeners has
value as a potential new drug candidate to prevent or treat diabetes.

Diabetes prevention by GT may result from its action on one or more of several
cell types, including APC (macrophages or dendritic cells), regulatory Th cells, effector Tc
or NK cells, or target islet B-cells.

If GT affects regulatory T cells, it may permit

restoration of certain subtypes of T cells, such as the critical RT6* T cells, since DP/BB

rats are known to have a low number of RT6+ T cells.

GT might also interfere with

cytokine production to change either cytokine types or quantity, block or enhance

cytokine-mediated effects or alter the balance of cells, dependent on the dynamics of
cytokine production. Since the DP/BB rat has an increased number of NK cells and few
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CD8’ Tc cells, if GT acts on effector cells, it may reduce the number or/and activity of NK
cells.

Hypothesis
The hypothesis for this study is that GT treatment prevents EDDM in DP/BB rats.

GT treatment would be expected to exert its effects on the immune system by elimination
of antigen presenting cells, or cytotoxic effectors or by altering the balance or function of

regulatory cells. Because apoptosis is known to be the mechanism for protection against
dangerous immunologic reactions, GT may act by inducing apoptosis of some types of

leukocytes.

GT may alter immunologic reactions by restoring other cells especially

regulatory T lymphocytes.

GT functions as an immunomodulator with immunosuppressive effects as revealed
by research completed in the past decade, and has been used to suppress immune
responses in transplantation. We reasoned that GT’s immunosuppressive function should

help to block the autoimmune process and prevent insulin dependent diabetes and possibly
other autoimmune diseases. GT treatment may be able to decrease the incidence of EDDM

or perhaps delay its onset in DP/BB rats.

Regulatory T lymphocytes, such as CD4" T cells, CD8+ T cells and RT6* T cells,
play a key role in EDDM development and it is appropriate to discover whether GT can

exert an effect on these cells or whether its effects are concentrated in the antigenpresenting or late effector stages of autoimmunity.

If regulatory T lymphocytes are

targetted by GT, the autoimmune process as well as EDDM in DP/BB rats may be
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prevented in a most advantageous manner since alteration of antigen presentation or
immune effector function may have a harmful effect on cancer surveillance and
antimicrobial immunity.

Apoptosis is considered an important mechanism by which the immune system
eliminates dangerous cells and limits immune responses. Apoptosis should help inhibit

autoimmunity and reduce untoward immune responses in the host.

Since one study

(Sutton et al. 1994) had reported that GT induced apoptosis in vitro, we proposed that

GT might also induce apoptosis in vivo and inhibit the autoimmune processes of IDDM,
although in vivo apoptosis induction by GT has never previously been demonstrated.

Significance of this research
The most important potential contributions of this project are 1) gaining new

insight into the way in which GT interferes with the development of autoimmunity with
IDDM as a model; 2) providing preliminary evidence that a new category of
chemopreventive agents may provide improved quality of life for those predisposed to
development of IDDM; and 3) having a better understanding of IDDM pathogenesis.

36

MATERIALS AND METHODS

Experimental Animals
Equal number of male and female diabetes prone BioBreeding (DP/BB) rats were

purchased from the National Institues of Health central breeding colony at the University
of Massachusetts Medical School (Worcester, MA). DP/BB rats were shipped in filter
crates and were maintained in isolation from other animals and humans (viral antibody free

conditions).

The vivarium performs periodic serologic testing on sentinal animals to

insure that specific pathogens have not entered the facility. Upon arrival, animals were

caged individually and given one week to become acclimated to the animal facility. The

environment was temperature and light (12 hours light/12 hours dark) controled. Animals
were provided food and water ad libitum. Water bottles were sterilize before reuse, but
food, water and bedding were not.

Standards for animal care of BB rats have been

published by Olsen et al (1990). Investigators and animal caretakers donned mask, cap,
gloves and gown before entering the animal rooms to avoid. All materials for these rats

were treated to minimize contamination.

Toxicity Study
RIN 38 cell cytotoxicity and function
The RINr 1046-38 (RIN 38) cell line was originally derived from an insulinoma.

This cell line was maintained in the laboratory of Dr. Bruce Chertow. To estimate the

highest concentration of GT which is non-toxic to P-cells, RIN 38 cells were grown 48
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hours in RPMI-1640 cell culture medium with 5% FBS and 2.8mM glucose at 37°C in a

C02 (5%) incubator. At the end of 48 hours, cells were washed with Krebs-Ringer buffer

(KRB).

To 1 ml of KRB, glucose (2.8 mM) was added to each well for a 1 hr pre-

incubation at 37°C in a CO2 (5%) incubator. This medium was aspirated, cells were
gently washed with KRB, and 1 ml KRB containing 2.8 or 16.7 mM glucose and gliotoxin
(0, 0.5,1, or 5 mg/ml) was added. Cells were incubated 1 hr at 37°C in a CO2 (5%)

incubator. Supernatant was removed after 500 x g centrifugation at 4°C. The supernatant
was frozen for RIA assay. The viable RIN 38 cell counts were determined by trypan blue

staining and counted with a hemacytometer.

Viable cells were counted as those that

excluded the blue stain.

The RIN 38 cells are insulin secreting and were used to assess effects of GT on

insulin secretion. To estimate the effect of GT on insulin secretion, RIA assay for insulin
was conducted in Dr. Chertow’s laboratory using the frozen supernatant mentioned above.

To iodinate insulin, 10 pl insulin (0.4pg/pl), 20 pl 0.25 M phosphate buffer

(pH7.5), 14.2 mCi ,25I and 15 pl chloramine were combined. After 45 seconds, 50 pl
metabisulfate and 25 pl 12.5% BSA were added in phosphate buffer. This mixture was

removed by passage through a carboxymethyl cellulose column in a syringe and washed
with 0.05 M phosphate buffer.

The sample was washed with 2.5% BSA and 0.5 ml

collected into each of six tubes. The tubes were counted by gamma counter and fractions

in the last two tubes were used as radiolabeled insulin.

Guinea pig anti-porcine insulin, which crossreacts with rat insulin was used at
1/500,000 dilution. A standard curve consisting of 0, 0.21, 0.58, 1.33, 2.83, 5.63, 11.25
ng insulin per ml was constructed. The samples were combined with the antibody for four
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hours at room temperature. Radiolabeled insulin was then added to each tube. After

overnight incubation, 2 ml of dextran-coated charcoal (25 mg/ml) was added to each tube

to remove unbound insulin and centrifuged for 20 minutes at 500 x g at 8 °C.

The

supernatant was counted on a gamma counter set for 125I for 12 minutes per tube.

Radioactivity of each unknown sample was compared to the standard curve to determine
insulin concentration. All samples were assayed in duplicate and results reported as mean.

Peripheral leukocyte counts

After receiving 10 doses of GT or vehicle, blood was collected from GT treated

and control rats preparing the rat’s tail with 70% isoproposol by snipping the tip of the tail
with alcohol-treated scissors. A drop of blood was allowed to form and 20 jil of blood
was drawn into a Unopette capillary (Becton-Dickinson, Rutherford, NJ).

Blood

specimens were diluted to 2 ml in buffered ammonium oxalate solution. After red cell
lysis, leukocyte count was performed microscopically with a hemacytometer and

expressed asleukocytes per milliliter.

Histology and Morphometry
Liver, kidney, spleen and pancreas tissues were removed from GT treated DP/BB
rats (diabetic and pre-diabetic) and untreated control DP/BB rats and placed in 10%

formaldehyde. The tissue samples were embedded in paraffin and 10 micron sections were

cut.
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Routine hematoxylin and eosin (H&E) staining were applied to make slides for

histological observations. The sections were covered with permount and coverslips. The
slides were stored in flat slide holders until permount dried.
For mophometric evaluation of splenic follicles a video camera with television

monitor was placed on the microscope and images of splenic follicles placed in the center
of the monitor’s viewing area. A vernier caliph was used to make measurements directly

from the monitor. All evaluations were done at the same magnification so results from

different tissues would be comparable.

Research Design (Immunology Studies)
To evaluate the effect of GT on relevant cells of the immune system, both direct

effects of GT on isolated spleen cells (in vitro study) and the effects resulting from chronic
animal treatment (in vivo study) were investigated. For these studies only non-diabetic
(pre-diabetic) animals were used. By harvesting cells at 65 days of age, we were assured

that all cells were recovered from pre-diabetic animals.

In vitro study
For the in vitro investigation of GT effects on splenic lymphocytes, untreated

DP/BB rats were sacrificed at 65 days of age and splenic cells were isolated as described
below. Half of the splenic cells were incubated for one hour with 1 |ig/ml GT at 37°C in a

CO2 (5%) incubator while the other half was cultured in GT-free cell culture medium as
the control. The suspending vehicle, ethanol, was added to each control sample in an

amount equal to that present in GT treated samples.
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Both GT treated samples and

controls were divided into two aliquots. One aliquot received 10 pg/ml concanavalin A

(ConA) stimulation and another remained unstimulated, yielding four different
preparations of splenic cells: (1) GT treated cells; (2) ConA stimulated GT treated cells;

(3) controls; and (4) ConA stimulated controls. These cells were then labeled with mAb
for lymphocyte surface markers, analyzed by TUNEL method for lymphocyte apoptosis,

or used in proliferation tests, each described below.

In vivo study
For in vivo study of lymphocytes from GT-treated rats, experimental animals were

placed into two groups. Half of these DP/BB rats were treated with 1 pg/g body weight

GT three times weekly (Monday, Wednesday and Friday) from 30 days of age and
continuing until 65 days of age. The remaining animals received the same volume of

suspending vehicle (glycerin) according to a schedule identical to that were for GT treated
rats.

All rats were monitored for weight gain to verify that they were not becoming

diabetic and were sacrificed at 65 days of age. Spllens and pancreases were recoverd and
used as described below.

Splenocytes from GT treated rats and control rats were divided into two aliquots.

One aliquot was stimulated with 10 jig/ml ConA and the remaining cells were kept
unstimulating. Four different samples were prepared: (1) splenocytes from GT treated

rats; (2) splenocytes from GT treated rats with ConA stimulation; (3) splenocytes from

control rats; (4) splenocytes from control rats with ConA stimulation. Samples were then
used for surface marker labeling, apoptosis analysis and proliferation testing as described

subsequently.
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In Vivo Gliotoxin Use

Treatment regimen

GT was obtained from Sigma Chemical Company (St. Louis, MO) and suspended

in sterile glycerol at a concentration of 1 mg/ml. Control group rats received suspending
vehicle only.

GT-treated animals received 1 jig/g of body weight three times weekly

(Monday, Wednesday and Friday). All injection were administered intraperitoneally and

volumes injected ranged from 0.1 to 0.25 ml depending on the weight of the animal.
Animals were monitored for development of diabetes throught the duration of their

treatment..

Diabetogenesis
The onset of diabetes was heralded by a decline in weight, positive urine glucose

test and confirmed by elevated blood glucose (>200 mg/dl). As soon as diabetes was
confirmed, the diabetic animals were painlessly euthanized by nembutal overdose and

exsanguination via cardiac puncture. Prior to each GT or control injection the animal was
weighed, the weight compared to the previous weighing and if there was a decline in

weight, urine was tested with a glucose test paper. If glycosuria was present, a small drop

of blood was obtained by snipping the tail with sterile scissors and the blood glucose was
measured with a glucose meter. The animal was considered diabetic if blood glucose was
greater than 200 mg/dl.
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Serum glucose measurement

Serum glucose was measured by the method of modified Keston’s procedure
(Raabo and Terkildsen, 1960). Blood from an experimental animal was allowed to clot on
ice. The clot was released from the sides of the tube with a wooden splint and blood was

centrifuged in the cold for 15 minutes at 900 x g. Serum was removed with a Pasteur
pipet and frozon at -20°C until analyzed.

Reagents for this test were obtained from Sigma Chemical Company (St.Louis,

MO). Water (2 ml) was added to a test tube as a blank control. Water (1.8 ml) and 0.2 ml
glucose standard solution (100 mg/dl) was added to another test tube as a standard.

Serum samples were prepared by precipitating of protein with Barium sulfate. Serum was
diluted 1:10 with distilled water to 2 ml. Diluted serum and mixed with 1 ml of 0.3 N zinc

sulfate.

Barium hydroxide (1ml, 0.3 N) was added.

After mixing well, 0.5 ml of

deproteinized serum supernatant was transfered to another tube and 5.0 ml combined

PGO enzymes (5 units/ml glucose oxidase and 1 units/ml peroxidase)-color reagent

solution (o-Dianisidine dihydrochloride 2.5mg/ml) was added. After mixing, tubes were
incubated at room temperature (18-25 °C) for 45 min.

At the end of the incubation

period, absorbance of samples was determined spectrophotometrically at 450 nm read.
Serum glucose values were calculated by the following equation:
Serum Glucose (mg/dl) = [Absorbance of Test / Absorbance of standard] x 100
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Immunologic Effects of Gliotoxin

Isolation of splenic leukocytes

As noted previously, in vitro lymphocytes studies employed cells from rats 65 days

of age. The in vivo GT treatment study employed splenic cells from rats treated with GT
or control injections during the period from age 30 days to 65 days.

At 65 days

experimental animals were euthanized by CO2. A midline incision was mad expose the

spleen which was aseptically removed and placed in 10 ml of Dulbecco's phosphate
buffered saline (PBS) on ice for transport from the vibarium to laboratory.

In the

laboratory, splenic tissue was minced and further disrupted by passage through a sterile 80

mesh tissue sieve using aseptic technique in a laminar-flow hood. Cells were dispersed by

repeated aspiration and expression with a sterile 21 gauge needle, washed twice with 15
ml of Dulbecco's PBS, and recovered by centrifugation at 1000 rpm for 4 min. Isolated

leukocytes were suspended in Eagle’s Minimum Essential Medium (MEM) with 10%
FCS, and unless otherwise noted, incubated in a 25 ml tissue culture flask in CO2 (5%) at

37°C to remove adherent cells. Viable cell counts of non-adherent cells were determined
by 0.4% trypan blue staining and counting in a hemacytometer.

All lymphocyte

preparations used in this study showed >95% viability.

Lymphocyte surface marker labeling
Splenic lymphocyte subsets were stained with antibodies against surface CD4,
CD8, NK, RT6, PanT and MHC II prior to flow cytometric analysis.

Reagents used

include mouse anti-rat CD4 (clone OX-35), CD8 (OX-8), PanT (OX-19) monoclonal

antibodies (mAb) which were purchased from Pharmingen, San Diego, CA. Mouse anti
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rat NK (3.2.3) mAb was purchased from Harlan Bioproducts, Indianapolis, IN. Mouse

anti rat RT6 (P4/6) and MHC II (OX-17) mAb were purchased from Biosource,
Camarillo, CA. With the exception of RT6, all antibodies were flurescent labled by the

supplier. Since anti RT6 mAb is unlabeled, a goat anti-mouse secondary antibody was
used to visualize the anti-RT6 antibody. The fluoresceint isothiocyanate (FITC)-labeled

secondary antibody was purchased from Sigma, San Louis, MO. FITC labeled anti CD8
mAb was paired with phycoerythrin (PE) labeled anti CD4 mAb for double staining. FITC

labeled NK mAb was paired with PE labeled PanT mAb for double staining.
To control for nonspecific staining by antibodies, FITC labeled mouse IgGl and
PE labeled mouse IgG2a isotype control antibodies were purchased from Sigma, St.
Louis, MO and used for each lymphocyte sample mentioned above.

Prior to analysis of lymphocyte surface markers, each antibody was titrated to

determine an ap propriate antibody dilution. Splenocytes from normal rats were used for

titration. Anti CD4 and CD8 mAbs were diluted 100 fold in PBS while other mAbs were
diluted 50 fold. Splenic lymphocytes were harvested by centrifugation and resuspended to

a concentration of 106 cells/ml in Dulbecco's PBS with 1% FBS. Splenic lymphocytes
were added to a series of tubes (105 cells/tube) and incubated with equal volumes of FITC

and PE labeled mAbs at appropriate dilutions for 30 minutes on ice. Stained cells were

washed three times with assay buffer (1 mg/ml sodium azide in PBS). The secondary

antibody was applied to unlabeled anti RT6 mAb after primary antibody binding. The

labeled cells were fixed by adding 500 pl of 4% paraformaldehyde. The fixed cells were
held at 4°C overnight for flow cytometry evaluation the next day.
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Flow cytometry
Flow cytometric analysis was performed in a FACScan flow cytometer (Becton

Dickinson Immunocytometry Systems, Mountain View, CA). The argon ion laser was

operated at 488 nm with 15 mW of power.

Fluorescence was determined using

logarithmic amplification. Forward scatter (FSC) and side scatter (SSC) were determined

using linear amplification. A Macintosh computer with Cell Quest® software was used to
record, convert and analyze data.
For each sample, the flow cytometer scanned at least 10,000 cells and recorded

four parameters: FSC, SSC, FITC staining (FL1) and PE staining (FL2). The lymphocyte
populations were gated from FSC and SSC plots and were replotted into a dot plot or a
histogram plot. The data derived from dot plot included the percentage of FITC or PE

labeled cells in total gated lymphocytes.

Evaluation of Fluorescent Intensity
The isotype control tests were conducted using FITC conjugated mouse IgGl and

PE conjugated mouse IgG2a antibody to determine any nonspecific staining as shown in

Figure 5. For analysis of CD4*, CD8+, CD5+ (PanT) MHC II+ and NK lymphocytes, we

first recognized and gated the lymphocyte populations on the FSC versus SSC dot plots.
The gated data were replotted as FITC (FL1) versus PE (FL2) dot plots. Quadrants were

drawn on the basis of stained versus unstained cells as determined by isotype control data

on regative control data to permit calculation the percent of cells in each quadrant.
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Figure 5. Example of isotype control data for primary antibodies. Isotype controls
were evaluated for each lymphocyte sample analyzed to establish the level of non-specific

staining expected from each of the primary antibodies (anti CD4, anti CD8, anti NK, anti

CD5, anti MHC II). The primary antibodies for CD8, MHC II and RT6 are mouse IgG2a
and others are mouse IgG.

Therefore the isotype control antibodies were FITC-

conjugated anti mouse IgG2oc mAb and PE conjugated anti mouse IgG mAb.

After

staining cells with isotype control antibodies, the lymphocytes were gated based on the

scatter plot (not shown) of cells in this preparation, and were replotted in the FL1-FL2
plot, of which this figure is an example. Since no specific staining of these cells was

possible, all cells in the FL1-FL2 plot are considered to be negative. Positive cells will

therefore be found to the right of the FL1 marker and above the FL2 quadrant markers.
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Isotype Control FITC

w4 •

Quadrants therefore represented FITC stained, PE unstained cells; FITC unstained, PE

stained cells; double stained and double negative cells (Figure 6).
Primary mouse anti-rat RT6 mAb is unlabeled so that an FITC conjugated
secondary goat anti mouse IgG mAb is required to visualize the RT6 staining. A
secondary antibody negative control was conducted to determine any nonspecific staining
as shown in Figure 7. The RT6+ lymphocyte data were first analyzed as CD4*, CD8+,

CD5* (PanT) and NK lymphocytes. Since DP/BB rats did not have a distinctly staining

RT6+ lymphocyte population, a count of RT6* staining lymphocytes was not possible. For
analyses of RT6+ cell data, we recognized and gated the lymphocyte population from FSC

versus SSC dot plots then replotted them to FITC (FL1) histogram plots (Figure 8). The
intensities of fluorescent staining for each dot were recorded as channel number and the

mean channel number representing the average fluorescent intensity of all cells with any
RT6 surface stain was calculated. A higher mean channel number represented a larger

number of RT6 molecules per cell. The data were normalized by dividing mean channel

numbers for experimental preparations by the average channel number for all samples
analyzed during a given flow cytometry section to produce a mean channel index.

Pancreatic immunohistology

Pancreatic tissue was removed from GT treated DP/BB rats and untreated control
rats, placed in 1 ml centrifuge tubes and immediately immersed in liquid nitrogen and then

moved to a -80°C freezer where they remained until sectioning.

Pancreatic tissue was embedded in Tissue Freezing Medium (Sakura Finetek, Inc.,
Torrance, CA) and sections were cut with a Cryocut 1800 cryostat (Reichert-Jung,
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Figure 6. Example of method used to identify % of cells positive for a given surface
marker. To evaluate the percentage of spleen lymphocytes bearing a particular surface
marker (MHC II shown here), rat splenocytes were incubated with fluorescent conjugated
antibodies (FITC-conjugated mouse anti rat MHC II mAb). The upper panel shows the

scatter plot of cells in this preparation with the gate selected for lymphocytes indicated by
the polygon shown between 200 and 600 on the forward scatter axis. The lower plot

indicates the staining seen among gated cells treated with the FITC-conjugated mouse anti

rat MHC II mAb. The antibody staining will only be seen in the FL1 channel and there is
no FL2 signal present. The right lower quadrant shows cells positive for FITC staining.

The cells in left-lower quadrant are considered to be negative. The table represents the
computerized tally of cells in each quadrant.
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Quad Events % Gated % Total
UL
UR
LL
LR

0
0
1137
624

0.00
0.00
64.57
35.43

0.00
0.00
11.37
6.24

Figure 7. Example of isotype control data for RT6 secondary antibody. For RT6
staining, the primary antibody is not fluorescent conjugated and is identified by labeled
secondary antibody. To evaluate the level of non-specific staining by secondary antibody,

rat splenocytes were incubated with FITC-conjugated goat anti-mouse IgG2a mAb, the

secondary stain for primary RT6 antibody. The upper panel shows an example of the
scatter plot of cells in this preparation with the gate selected for lymphocytes indicated by
the polygon shown between 200 and 400 on the forward scatter axis. The lower plot

indicates the staining seen among cells treated with the secondary antibody, with the
secondary antibody only seen in the FL1 channel since there is no FL2 signal present.

Since no specific staining of these cells is possible, all cells in the FL1-FL2 plot are
considered to be negative. RT6 positive cells will therefore be found to the right of the

FL 1 quadrant marker.
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Figure 8.

Example of mean channel number calculation for RT6+ cell surface

markers.

To evaluate the intensity of RT6+ staining on spleen lymphocytes, rat

splenocytes were first incubated with mouse anti-rat RT6 primary antibody, then
visualized by FITC-conjugated mouse anti-rat RT6 mAb.

The upper panel shows the

scatter plot of cells in this preparation with the gate selected for lymphocytes as indicated

by the polygon shown between 200 and 400 on the forward scatter axis.

The lower

histogram plot indicates the number of cells (y axis) with a given fluorescent intensity (x

axis) seen among gated cells.

The average fluorescent intensity of the analyzed cell

population appear in the table below the histogram.
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Deerfield, IL) at -20°C to a thickness of 10 microns.

The sections were laid on

Vectabond reagent (Vector Laboratory Inc., Burlingame, CA) coated slides. The slides

were stored at -20 ° C overnight. After bringing slides to room temperature, they were

fixed by immersion in acetone for 5 minutes at room temperature.
After washing with PBS, the slides were incubated in a humidified chamber at

room temperature for 20 minutes covered with 1:50 dilution of horse serum (Vector
Laboratory Inc., Burlingame, CA) to block nonspecific antibody binding.

The tissue

sections were then covered with fluorescent labeled specific primary antibody (1:1000

dilution of mouse anti-rat monoclonal antibody) at room temperature for 30 minutes in a
humidified chamber. After staining, the slides were rinsed with distilled water.

Since

mouse anti-rat RT6 mAb is unlabeled, the tissue sections stained for RT6 were
subsequently incubated with secondary antibody (1:1000 dilution of FITC labeled rat

absorbed-goat anti-mouse antibody) for 30 minutes.

The slides were placed on a

horizontal surface and two drops of Gel/Mount (Fisher Scientific Co. Pittsburgh, PA)

applied on the tissue sections. Coverslips were carefully placed on top of the mounting

fluid, and the borders of the coverslip were sealed with permount.

Functional Evaluation
Leukocyte proliferation
As with the earlier experiments, lymphocytes for in vitro study were isolated from

spleens of 65-day-old GT untreated DP/BB rats and treated with 1 jig/ml GT in tissue

culture flasks for 1 hour prior to proliferation testing. Lymphocytes from the in vivo study

were isolated from GT treated DP/BB rat spleen and their corresponding controls which
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had been treated with vehicle only. Splenic lymphocytes were stimulated with ConA and
proliferation was measured by a dye-reduction assay. Briefly, isolated splenic leukocyte

suspensions were centrifuged in 15 ml test tubes in 500 x g for 4 minutes at 4 °C. Cell
pellets were resuspended in complete MEM-10 (Sigma, St. Louis, MO).

Leukocyte

suspension and ConA solution were added to a 96-well microtiter plate (105 cells/well)

with three wells for each sample.

Cells in control wells were incubated with MEM

medium only. The final concentration of ConA was 10 jig/ml. Alimar Blue (50 pl/well)
(Sensititre/Alamar, Sacramento, CA) was then added to each of these wells. Samples in

microtiter plates were incubated in a humidified 37 °C, CO2 (5%) incubator for 72 hours.
Proliferation test data were obtained from a microplate reader set to measure absorbance

at 590 nm. The average absorbance of triplicate wells was used to calculate a stimulation
index (SI) where SI

(Absorbance of sample with mitogen stimulation)/(Absorbance of

sample without mitogen stimulation). The data were statistically analyzed by t test.

Apoptosis
Splenic lymphocytes isolated from GT treated DP/BB rats, controls, or splenic

lymphocytes treated with GT in vitro and control lymphocytes were stained by the

TUNEL method (terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick

labeling) with Oncor Fluorescent ApopTag Kit (Oncor, Inc, Gaithersburg, MD) and
analyzed by Becton Dickenson FACScan flow cytometry to determine the proportion of
lymphocytes undergoing apoptosis. The TUNEL procedure measures elevated levels of

free 3'-hydroxy DNA fragments.
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In the TUNEL method,

lymphocyte DNA is first

tailed by terminal

deoxynucleotidyl transferase (TdT) to add digoxigenin-deoxyribonucleotide triphosphate
to the 3'-OH ends of fragmented double or single stranded DNA. Then digoxigenin-11 -

dUTP and dATP are bound by anti-digoxigenin antibody conjugated with FITC.

All

lymphocytes were counterstained by propidium iodide (PI).

To conduct the apoptosis analysis, 4 x 106 isolated leukocytes were recovered by

centrifugation (500 x g) and fixed in 5 ml ice-cold 1% Paraformaldehyde in PBS at pH 7.4
for 15 minutes. The fixed leukocytes were washed three times with PBS. The cells were

recovered by centrifugation at 1000 rpm in 5 minutes.

The fixed leukocytes were

resuspended in 70% ice-cold ethanol and kept at -20°C up to 5 days.
For each sample, 2 x 106 cells per sample were recovered by centrifugation and

resuspended in 1 ml PBS. After two washes with PBS, the cells were resuspended in two
drops of proprietary equilibration buffer. The cells were spun down and resuspended in
50 pl of working strength TdT enzyme, and incubated in a water bath for 30 minutes at

37°C. the reaction was stopped by adding 1 ml stop/wash buffer directly to the cell
suspension.

Cells were then washed twice with the buffer, resuspended in 100 pl of

working strength anti-digoxigenin-fluorescein and incubated for 30 min at room
temperature. After incubation, the cells were washed twice by 1.0 ml of 0.1% Triton X-

100 in PBS. The cells were stained by 1.0 ml of propidium iodide staining solution for 15
minutes at room temperature in the dark.
Green fluorescence of anti-digoxigenin-fluorescein was measured at 510-550 nm

by the flow cytometer while red fluorescence of PI was measured at >620 nm.
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For analyses of apoptosis data, we first gated the lymphocyte populations from

FSC versus SSC dot plots then replotted them as FITC (FL1) versus PI (FL2) plots. To

establish the fluorescent intensity that identifies apoptotic vervus non-apoptotic cells, cell
suspension were divided and stained by methods to produce positive and negative

controls. The positive samples were stained with the complete stain (TUNEL procedure
with FITC; counter stain with PI) and the negative controls were stained with counter
stain (TUNNEL procedure used but with omission of FITC conjugated anti-digoxigenin

antibody plus PI counter stain). These cells were analyzed by flow cytometry as shown in

Figure 9 which indicates the level of FL1 staining associated with apoptotic cells. The
intensity of the FL2 channels indicates PI staining associated with all cells. The highest
intensity level of each parallel negative control sample was regarded as the lowest level

consistent with a positive apoptosis staining reaction. The dots with greater staining
intensity beyond this level was considered to represent apoptotic cells. The percentage of

cells showing apoptosis was determined and comparisons made as noted in the results.

Statistical Analysis
Analysis of the incidence and onset of EDDM in DP/BB rats was performed using

life-table analysis (Ingelfinger, 1987). All other comparisons between GT treated samples
and controls as well as proliferative and apoptosis data yielded continuous data was

therefor evaluated by student’s t-test using a computerized statistical program in Sigma
Plot (Jandel corporation, San Rafael, CA).
Samples for the in vitro portion of the test used aliquots of identical cell

preparations allowing a paired t-test for the evaluations. The in vivo portion of the study
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Figure 9. Sample data to illustrate counting of apoptotic cells. Lymphocyte samples

containing apoptotic cells were treated with the complete stain (TUNEL procedure with
FITC; counter stained with PI) and the negative controls were prepared by exposure to
the counter stain only. The % of cells showing apoptosis (FITC staining) was determined

by flow cytometry with 10,000 cells analyzed. The highest FL1 intensity level of each

parallel negative control sample (shown in the upper panel) was regarded as the highest

level consistent with negative apoptosis staining (shown in lower panel). The quadrant
was drawn at the highest intensity level of each negative control sample. The cells located

in upper-right quadrant of the lower panel were counted as apoptotic lymphocytes.
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was derived from rats which had no one to one corespondance between GT treated and
control animals. Therefore an unpaired t-test was used for in vivo derived data.
ANOVA was used to evaluate insulin release data and was performed using PC-

SAS.
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RESULTS

Toxicity of Gliotoxin
Early studies in our laboratory and in other laboratories indicated that GT is an

immunomodulator with immunosuppressive functions. Although we wished to study GT
as an immunotherapeutic/immunopreventive compound, it was essential to determine if

doses which may exhibit beneficial effects on an autoimmune processes and prevent

autoimmune diseases also produced unacceptable toxicity. Previous studies showed that
gliotoxin at >100 pg /mouse produced lethal effects (Eichner, et al., 1986). However we
have shown that concentrations as low as 1 pg/ml affected phagocytic activity of PMN.
To predict what level of GT exposure might suppress lymphatic cells without destruction

or enhancement of damage to insulin-secreting cells, GT toxicity was evaluated by several

methods including its effect on cultured cells as well as its effect on intact animals.

RIN 38 cell viability
As shown in Figure 10, GT concentrations of 0.5 and 1 pg/ml did not alter the

viability of RIN 38 cells. GT at 5 pg/ml was lethal for RIN 38 cells. The concentration of

glucose in the incubation medium had no appreciable effect on RIN 38 viability as shown
by cells exposed to GT in the presence of 2.8 mM (Figure 10, upper panel) or 16.7 mM

(Figure 10, lower panel) glucose. The higher glucose concentration was neither protective

for high GT doses nor did it enhance toxicity of lower GT concentrations. Because 1

63

Figure 10. Viability of RIN 38 cells after exposure to GT. RIN 38 insulinoma cells

were cultured for 48 hours in RPMI-1640 with 5% FBS and 2.8 mM glucose at 37°C in a
CO2 (5%) incubator. After preincubation in Krebs-Ringer buffer (KRB) for 1 hour, the

cells were incubated with GT (0, 0.5, 1 and 5 pg/ml) with low glucose concentration (2.8
mM, upper panel) or high glucose concentration (16.7 mM, lower panel) for 1 hour. All

conditions were tested in triplicate. The viability of RIN 38 cell counts were determined
by trypan blue staining. The columns indicate the percentage of viable RIN 38 cells.

Standard errors did not exceed 0.2% of the mean values.
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|ig/ml GT had previously been shown to affect PMN function, we were interested to know
if an equivalent dose would be tolerated by p cells.

REN 38 cell insulin secretion

GT treated RIN 38 cells produced less insulin than controls (Figure 11). RIN 38
cells were incubated in 2 concentrations of glucose (2.8 mM glucose, upper panel; 16.7
mM glucose, lower panel) and provided similar results under both conditions.

Cells

treated with 5 pg/ml GT were nonviabie (see Figure 10) so insulin release at this
concentration from these cells was not physiologic, but due to lysis. Although 1 pg/ml
GT decreased insulin secretion, more than 70% insulin remains available and would not

likely eliminate insulin production if given to experimental animals.
From these results, we reasoned that a dose equivalent to 1 pg/g of body weight

would probably not cause significant harm to pancreatic B cells either in terms of B cell
viability or function, but as noted before, this level of GT may have an effect on lymphoid

cell function.

Although it would be necessary to conduct in vivo evaluation, the cell

culture results suggested that GT treatment would probably not be a cause of diabetes.

Treatment of BB rats with GT gave us the opportunity to attempt to document any

evidence of systemic toxicity as suggested by the overall health of treated animals. The
animals in this initial trial were given up to 36 injections of GT which provided an oppor
tunity to note any gross toxicity by comparing GT treated animals to those given control

(glycerin vehicle) injections. We did not observe any untoward effects of chronic GT
treatment. Among those animals not developing diabetes, both control and GT-treated

animals appeared equally healthy. Fur remained sleek and unruffled, the animals were not
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Figure 11. Effect of GT on insulin secretion by RIN 38 cells. Insulin release from RIN
38 cells was measured by RIA with low glucose medium (upper panel) and high glucose

medium (lower panel). Mean insulin values for culture with 0-5 jig/ml GT are shown;
error bars represent standard error of the mean. Each condition was tested in sextuplicate

culture after 1 hour of GT incubation. ANOVA for low glucose conditions (general linear

models procedure for completely randomized 2-factor ANOVA) showed marginal nonsignificance (p=0.069).

Because these data approached significance, a Tukey HSD

(honestly significant difference) test was performed as a follow up. Tukey HSD showed

that at p=0.05 the controls with or without ethanol were not significantly different but

insulin secretion at each of the 3 GT test concentrations differed from their respective
controls. Similar results were obtained for high glucose concentration.
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lethargic, eyes and mucosa appeared normal, food and water consumption were unaffected, and there was no other evidence of cumulative toxicity (diarrhea, neurologic signs

for example) associated with prolonged GT treatment. All of these observations, how
ever, were subjective.

Several objective indicators of toxicity were recorded for GT

treated rats and their corresponding controls.

Effect on body weight

During the initial month of the in vivo studies, experimental animals were young

and rapidly gaining weight. Each animal was weighed three times weekly corresponding
to the times when GT or control injections were administered and the rate of weight gain

was used as an objective measure of the safety of GT treatment. Because males and fe
males attain different body weights, weight gain data was analyzed by gender. The history
of weight gain for females (Figure 12, upper panel) and males (Figure 12, lower panel)
treated with GT paralleled weight gain by controls. This data was further analyzed as av

erage daily weight gain and summarized in Figure 13. As expected, there was no statistical
difference between GT treated and control animals with respect to weight gain.

Leukocyte counts
One concern about the use of immunosuppressive drugs is the possibility that they
may compromise host defense against infections.

Therefore, the effect of GT on

peripheral blood leukocyte counts was measured in blood samples from non-diabetic

DP/BB rats treated with GT (1 pg/g of body weight) three times weekly for a total of 10
doses and compared to blood counts from control animals injected with vehicle on an
69

Figure 12.

Average body weight of DP/BB rats treated with GT or control

injections.

Five female and 5 male DP/BB rats were treated with GT (lpg/g body

weight, intraperitoneal injection) three times weekly beginning at 30 days of age. The

same number of rats received vehicle (glycerin) only. The weight was recorded for each

animal from 30 to 65 days of age and the average weight of each group was plotted.
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Figure 13. Average daily weight gain of DP/BB rats. Data from figure 11 was used to
calculate the average weight gain for each group (5 rats per group) expressed on a daily

basis. The columns indicate the average daily weight gain with the standard error of the
mean shown. Statistical comparison employed unpaired t-test.
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identical treatment schedule.

These data were reported by gender (Figure 14).

The

leukocyte counts of GT treated and control in female or male DP/BB rats were not

statistically different.

Histopathology
The liver provides an efficient system for extracting toxins from blood resulting in
their catabolism, storage, and/or excretion into bile. The sequestration of toxins by the

liver makes it a key organ for evaluating potential toxic effects of GT. The portal tract
contains a branch of the portal vein, a hepatic arteriole, and a bile duct. Blood entering

the portal tract through the portal vein and hepatic artery is mixed in the penetrating ves
sels, enters the sinusoids and percolates along the cords of parenchymal cells

(hepatocytes), eventually flowing into terminal hepatic venules, and exits the liver through
the hepatic vein. In histologic observations, the portal area may be the most important

region to observe toxic effects of toxins, including those related to GT treatment (Mary,

1993). Figure 15 shows H&E stained sections of liver from GT treated and control non
diabetic rats taken from an area near the portal tract. No clear morphological difference

was noted in these two sections.
Tissue regeneration, indicated by multi-nucleate cells, signifies cellular response to
toxic effects and examples of liver binucleate cells are identified in Figure 15

Cellular

vacuolization also indicates toxicity. In the observation of GT toxicity, binucleate cells

and cell vacuolization in the portal area of the liver were recorded in GT untreated, non
diabetic DP/BB rat liver sections and GT treated non-diabetic DP/BB rat liver sections.

Figure 16 shows the number of binucleate cells counted in the portal area in liver sections.
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Figure 14. Peripheral leukocyte counts in GT treated and control rats. BB rats (4

males and 4 females) were treated with GT (1 jig/g body weight, intraperitoneal injection)
from 30 days of age and the same number of rats received vehicle (glycerin) only as
controls. After 10 GT injections, 20 pl of blood was collected from the tail with Unopette

microcollection system.

microscopically.

After lysis of red cells, the leukocytes were counted

The columns indicate the leukocyte counts and error bars show the

standard error of the mean. Male and female data is shown separately because male rats
typically have higher absolute white blood counts than females.
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Figure 15. Liver morphology of GT treated and control nondiabetic DP/BB rats.

DP/BB rats were injected three times weekly with GT (Ipg/g body weight, intraperitoneal
injection) from 30 days of age to 90 days of age and euthanized prior to diabetes

development. The livers were removed and fixed in 10% formalaldehyde then embedded

in paraffin. The 10 micron liver sections were cut and stained with hematoxylin and eosin
(H&E). The upper panel is the portal area of liver section (lOOx) from a control rat and
the lower panel is from a GT treated rat. Exemplary binucleate cells are marked with

arrows. PT indicates the portal tract.
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Figure 16.

Prevalence of binucleate cells in liver sections from GT treated and

control DP/BB rats. H&E stained liver sections (c.f Figure 15) were evaluated for
binucleate cells after GT or control injections. The binucleate cells in portal regions of

liver sections which reflect the degree of regeneration in response to hepatic damage, were

counted in 8 high-power fields per rat. The columns indicate the number of fields counted
“n”; the average number of binucleate cells in each microscopic field (400x); and error

bars show the standard error of the mean.
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No difference in this measure of toxicity was found. No clear evidence of vacuolization

was seen in GT treated animals.
Since various toxins and drugs may be concentrated and excreted by kidney, it also
provides an important organ for evaluation of systemic toxicity. Typical signs of

glomerulus toxicity include protein precipitation, cell regeneration and cell vacuolization.
We did not see any increase of these characteristics in GT treated non-diabetic DP/BB rat

kidney sections (Figure 17) compared to untreated non-diabetic DP/BB rat kidney sec

tions.

Gliotoxin Effect on Diabetogenesis
Incidence and time of onset
To determine whether the immunomodulating effects of GT can influence

progression of autoimmune diabetes, DP/BB rats were treated with GT or vehicle starting
at 30 days of age and continuing through 120 days. We monitored IDDM onset on the

basis of weight loss, glycosuria and blood glucose levels when necessary.

Our

observations indicated that GT treatment diminished incidence and delayed onset of
IDDM pathogenesis if begun at 30 days of age.

As shown in Figure 18, 9 of 10 GT untreated control rats turned diabetic between
age 60-120 days.

This 90% diabetes incidence was comparable to the 86% average

incidence of diabetes among DP/BB rats reported in the literature. Only 5 of 9 GT treated

experimental DP/BB rats developed diabetes. When these data were evaluated by means
of life table analysis, GT treatment proved significantly protective. GT treatment started
from the age of 40 days was not protective Figure 19.
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Figure 17. Kidney morphology of GT treated and control nondiabetic DP/BB rats.
DP/BB rats were injected three times weekly with GT (1 pg/g body weight, intraperitoneal

injection) from 30 days of age to 90 days of age and euthanized prior to diabetes
development.

The kidneys were removed and fixed in 10% formalaldehyde then

embedded in paraffin.

The 10 micron kidney sections were cut and stained with

hematoxylin and eosin (H&E). The upper panel is the section from a control rat and the
lower panel is from a GT treated rat. “G” represents the glomerular structure and “T”

represents renal tubules.
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Figure 18.

Survival curves of GT treated DP/BB rats and untreated controls

(Treatment started at 30 days of age). Two groups of DP/BB rats, 10 rats per group
were injected with GT (Ijig/g body weight, intraperitoneal injection) or with vehicle three

times weekly beginning at 30 days of age through 120 days of age. The onset of diabetes

was determined by weight loss, glycosuria, and hyperglycemia.

compared using life table analysis.
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Figure 19.

Survival curves of GT treated DP/BB rats and untreated controls

(Treatment started at 40 days of age). Two groups of DP/BB rats, 10 rats per group
were injected with GT (Ijig/g body weight, intraperitoneal injection) or with vehicle three
times weekly beginning at 40 days of age through 120 days of age. The onset of diabetes

was determined by weight loss, glycosuria, and hyperglycemia.

compared using life table analysis.
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Serum glucose

Elevated blood glucose is a hallmark of IDDM. Destruction of pancreatic islet p
cells results in lower insulin production and reduced glucose metabolism. The primary

diagnostic test for IDDM is measurement of the blood glucose concentration. Blood sam-

pies were taken from DP/BB rats that had been treated with GT three times a week begin
ning at 30 days of age and from control rats. At the time these animals were euthanized

they were 90 days of age and non-diabetic. Figure 20 shows that among these pre
diabetic animals, GT treated rats maintained lower blood glucose levels.

The GT un-

treated rats were not clinically diabetic, that is, they had not begun to show weight loss or
glycosuria, but their serum glucose levels had moved into a range consistent with devel

oping disease. These data confirm the results of diminished diabetes incidence among GT
treated rats and imply that even among rats that will eventually become diabetic, the GT
treatment postpones their catastrophic collapse into overt disease.

Immunologic Effects of Gliotoxin
Spleen histology
The spleen contains peripheral (secondary) lymphoid tissue. Its functions include

filtration of blood and trapping blood-borne antigens and participation in the initial im
mune response to all invasive and particulate pathogens. The spleen is surrounded by a

thin, glistening connective tissue capsule.

The splenic white pulp consists of follicles

which contain many T lymphocytes. The red pulp is organized with sinuses which are

lined with macrophages, lymphocytes and plasma cells.
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Figure 20. Effect of GT on serum glucose levels of prediabetic DP/BB rats. DP/BB
rats were treated with GT (Ipg/g body weight, intraperitoneal injection) three times

weekly from 30 days of age to 90 days of age. The control group received injections of

vehicle (glycerin) on a schedule identical to that used for GT-treated rats. Serum samples
were collected from animals at 90 days of age and glucose concentrations measured with
the glucose oxidase procedure. The bars indicate the mean serum glucose concentration,

error bars show the standard error of the mean, and “n” indicates the number of rats
tested.
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Histology of H&E stained spleen sections from GT treated pre-diabetic or non-GT

treated prediabetic BB rats showed that GT treatment causes histologic changes which are
primarily manifest in the T cell dominant white pulp. The splenic follicles appeared to
have decreased prominence in GT treated rat spleen sections, compared to untreated con
trols as shown by Figure 21. The outer layer of the splenic follicle, ordinarily rich with T-

cells, clearly decreased in GT treated spleen sections. Meanwhile, the red pulp area be

comes more prominent as the white pulp decreases. We were able to morphometrically

document the changes in splenic follicles in GT treated animals. Follicles were examined
microscopically and the radius of medulla and thickness of the cortex measured directly

from a video monitor attached to the microscope. The mathematical relationship of me
dullary radius to cortical thickness is reported in Figure 22 for 24 GT treated follicles from

3 GT-treated animals and 16 sections from 2 control animals among GT treated compared
to control rats

GT produced effects in the spleen consistent with altered lymphocyte abundance

which may either involve all lymphocytes or may preferentially influence only a subset of
lymphoid cells. To have optimum utility, an immunopharmacologic agent should produce
a selective effect. Therefore the next phase of this study investigated whether GT may

have global or selective effects on lymphocyte subsets with particular relevance to IDDM.

Cells with MHC class II surface proteins

Autoantigen processing and presentation are important first steps in autoimmune
disease pathogenesis, especially in organ specific autoimmune diseases such as IDDM.
The loss of MHC II positive cells could provide an indicator of the loss of antigen pre-

91
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Figure 21.

Splenic follicle morphology of GT treated and control DP/BB rats.

DP/BB rats were injected three times weekly with GT (1 jig/g body weight,
intraperitoneal injection) from 30 days of age to 90 days of age and euthanized prior to

diabetes development. The spleen samples were removed and fixed in 10% formaldehyde,
then embedded in paraffin. The 10 micron spleen sections were cut and stained with
hematoxylin and eosin (H&E). The upper panel shows a splenic follicle from a control rat

and the lower panel shows a typical splenic follicle from a GT treated rat. The medulla in
each photograph is indicated by vertical markers and • the entire follicle (cortex and

medulla) is marked by horizontal lines.
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Figure 22. Effect of GT on splenic follicle morphology from DP/BB rats. DP/BB rats

were injected three times weekly with GT (1 pg/g body weight, intraperitoneal injection)

from 30 days of age to 90 days of age and euthanized prior to diabetes development. The
spleen samples were removed and fixed in 10% formaldehyde, then embedded in paraffin.
The 10 micron spleen sections were stained with hematoxylin and eosin (H&E).

The

cortical thickness and medullary radius of the splenic white pulp follicles were measured

directly from a video image. Morphometric analysis was made from observation of 8 low-

power fields from each rat. Data are represented as the thickness of the cortex divided by

the radius of the medulla for each follicle. The columns indicate the mean value of the
cortex-medulla ratio, error bars show the standard error of the mean, and “n” is the
number of follicles counted.
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senting ability that may contribute to decreased autoimmune disease. The effect of GT on
leukocytes with MHC II expression was investigated following in vitro GT treatment of
splenocyte suspensions. Spleen cell preparations were incubated with FITC conjugated

mouse anti rat MHC class II mAb and measured by flow cytometry. These cell suspen
sions were not pre-incubated in plastic flasks to remove adherent cells as subsequent

studies of lymphocytes were. Initially flow cytometry data for MHC II stained cells was

evaluated by gating on a region containing lymphocytes. Figure 23 shows that there was

no significant effect of GT on this populations of cells (upper panel). Likewise ConA

treatment (lower panel) of these cells did not reveal a distinction between GT treated cell
suspensions and control cells.

Because a more relevant population of cells would be those which are larger and

perhaps more granular than those contained in the lymphocyte gate, we reanalyzed the

data with a different gate as shown in Figure 24. GT did have a significant effect on MHC
II positive cells in this analysis as illustrated by Figure 25. ConA served to widen the dif

ference between GT treated and control cells. The number of cells included in this larger

gate was relatively small so that it is difficult to consider this finding conclusive with re
gard to antigen presentation.

NK cells
Many studies indicate that NK cells are major attackers of pancreatic islet £ cells
(reviewed in introduction). If these cells are susceptible to GT then this would imply that

some or all of the beneficial effects of GT may occur at the effector stage of IDDM

pathogenesis.
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Figure 23. Effect of GT on MHC H+ DP/BB rat splenic lymphocytes exposed to GT
in vitro. Spleen cell cultures were divided into 4 aliquots, and 2 aliquots were treated

with GT (1 jig/ml) for 1 hour at 37°C in a CO2 (5%) incubator and one GT treated aliquot
was subsequently incubated with ConA (10 |ig/ml) for 1 hour at 37°C in a CO2 (5%)

incubator. Half of the non-GT treated control cells were also stimulated with ConA and

the remainder served as unstimulated controls.

Cultures were stained with FITC-

conjugated anti-MHC II antibody and staining evaluated by flow cytometry with 10,000

cells analyzed. Columns indicate the mean % of cells staining for the MHC II marker,
error bars show the standard error of the mean, and “n” indicates the number of rats

evaluated.
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Figure 24. Example to illustrate two different gates used for MHC II data analysis.
To evaluate the percentage of spleen lymphocytes bearing MHC II surface markers, the
lymphocyte population was gated as other lymphocyte subsets (CD8+, NK subsets for

example). This gate is the small polygon shown between 300 and 500 on the forward
scatter axis in the upper panel. To analyze large cells such as granulocytes, monocytes
and macrophages, a wider gate was used (large polygon, upper panel) to include cells

with higher granularity and larger size. This gate (R3) is shown between 500 and 900 on
the forward scatter axis in the upper panel. The cells encompassed by gate R3 were
replotted in the lower panel. The lower plot indicates the staining seen among gated cells

treated with the FITC-conjugated mouse anti rat MHC II mAb. The antibody staining will

only be seen in the FL1 channel and there is no FL2 signal present.

The right lower

quadrant shows cells with positive MHC II antibody staining. The cells in the left-lower

quadrant are considered to be negative.
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Figure 25. Effect of GT on MHC H positive cells gated for granulocytes, monocytes

and macrophages. Spleen cells from 65 day old DP/BB rats were divided into 4 aliquots.

Two aliquots were treated with GT (1 pg/ml) for 1 hour at 37°C in a CO2 (5%) incubator
and one GT treated aliquot was subsequently incubated with ConA (10 |ig/ml) for 1 hour
at 37°C in a CO2 (5%) incubator. The other two aluquots of the GT untreated control

cells were also stimulated with ConA and the remainder served as unstimulated controls.
Cultures were stained with FITC-conjugated anti-MHC II antibody and staining evaluated
by flow cytometry with 10,000 cells analyzed. The cells gated by gate R3 in this analysis

were the splenocytes larger than those gated in Figure 23. Columns indicate the mean %

of cells staining for the MHC II marker, error bars show the standard error of the mean,

and “n” indicates the number of rats evaluated.
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GT effects on NK lymphocytes were first studied in vitro. Splenic lymphocytes
were isolated from GT untreated, 65 day-old, nondiabetic DP/BB rats. Cells were incu

bated for 1 hour with GT and labeled with FITC conjugated anti NK mAb. The percentage of FITC labeled lymphocytes was counted by flow cytometry. The experiments were

performed with or without superimposed ConA stimulation.

As shown in Figure 26, GT treatment (upper panel) increased the relative NK cell
percentage, but with ConA stimulation (lower panel), no difference was seen. These data

suggested that GT does not exert its effects on IDDM through NK suppression. NK

staining of lymphocytes from animals treated with GT compared to the untreated controls
showed no difference regardless of whether the cell suspension was exposed to ConA or

not (Figure 27). This further reduced the likelihood that NK cells represent the chief tar

get of GT.

CD5+ lymphocytes
Emphasis has been placed on cell-mediated damage in LDDM and less on humoral

mechanisms. Furthermore our observations reflect that GT may have an effect on morphological changes of splenic white pulp. Therefore, we focused attention on T-cells and

subsequently on their subpopulations. A PanT stain was used to evaluate the percentage
of cells bearing the CD5 marker and was applied to both in vitro and in vivo experiments.
Lymphocytes were recovered from 65 day old prediabetic DP/BB rats for in vitro study.

These cells were treated with GT or vehicle and aliquots were stimulated with ConA or
left unstimulated. A PE labeled mouse anti rat CDS monoclonal antibody was used for

flow cytometer enumeration of stained cells.
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Figure 26.

Effect of GT on DP/BB rat splenic NK cells exposed to GT in vitro.

Spleen cells from 65 day old DP/BB rats were obtained and preincubated for 1 hour at

37°C in MEM plus 10% FCS in polystyrene flasks in a CO2 (5%) incubator. Cultures
were divided into 4 aliquots, and 2 aliquots were treated with GT (1 pg/ml) for 1 hour at
37°C in a CO2 (5%) incubator and one GT treated aliquot was subsequently incubated

with ConA (10 p.g/ml) for 1 hour at 37°C in a CO2 (5%) incubator. Half of the non-GT
treated control cells were also stimulated with ConA and the remainder served as

unstimulated controls. Cultures were stained with FITC-conjugated anti-NK antibody and
staining evaluated by flow cytometry with 10,000 cells analyzed. Columns indicate the

mean % of cells staining for the NK marker, error bars show the standard error of the

mean, and “n” indicates the number of rats evaluated.
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Figure 27. Effect of in vivo GT treatment on splenic NK cells from DP/BB rats.
Treatment of DP/BB rats with GT (1 pg/g body weight, intraperitoneal injection) or

vehicle began at 30 days of age and continued until 65 days of age. Spleens were obtained

and splenocytes were recovered. Spleen cell suspensions were preincubated for 1 hour in
MEM plus 10% FCS in polystyrene flasks at 37°C in a CO2 (5%) incubator. Splenocyte

preparations were divided and half subsequently stimulated with ConA (10 jig/ml) for 1

hour. Cells were stained with FITC-conjugated anti-NK antibody and staining evaluated

by flow cytometry with 10,000 cells analyzed. Columns indicate the mean % of cells
staining for the NK marker, error bars show the standard error of the mean, and

indicates the number of rats evaluated.
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PanT staining did not show a response to GT treatment in vitro (Figure 28) and
ConA had no effect on these data. GT or vehicle was injected into DP/BB rats for the in

vivo phase of the study. As shown by Figure 29, the results were also very similar be-

tween GT treated and control groups. ConA stimulation provided no additional effect on
these data.

CD8+ lymphocytes
The importance of lymphocytes bearing the CD8 phenotype resides in their func
tions as cytotoxic effectors and also as regulatory cells. Both of these effects may be op

erative in IDDM and GT treatment could intervene at the level of CD8 lymphocyte abun
dance and function.

CD8+ T splenic lymphocytes were evaluated in a method similar to that in the
studies of CD5" cells. Lymphocytes incubated with GT in vitro, without ConA stimula

tion, showed a relative increase in CD8+ lymphocytes (Figure 30) and this difference was

enhanced by ConA stimulation to 53% above counts obtained in the absence of GT treat

ment. The results obtained from in vivo treatment with GT were not as pronounced and
ConA did not serve to create a distinction between in vivo GT treated CD8+ lymphocytes

(Figure 31).

CD4+ lymphocytes

CD4' T lymphocyte subsets include many different regulatory T cell types and play
important roles in immune and autoimmune processes. We determined whether GT alters
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Figure 28. Effect of GT on CD5+ DP/BB rat splenic lymphocytes exposed to GT in

vitro. Spleen cells from 65 day old DP/BB rats were obtained and preincubated for 1 hour
at 37°C in MEM plus 10% FCS in polystyrene flasks in a CO2 (5%) incubator. Cultures

were divided into 4 aliquots, and 2 aliquots were treated with GT (1 jig/ml) for 1 hour at
37°C in a CO2 (5%) incubator and one GT treated aliquot was subsequently incubated

with ConA (10 pg/ml) for 1 hour at 37°C in a CO2 (5%) incubator. Half of the non-GT

treated control cells were also stimulated with ConA and the remainder served as

unstimulated controls. Cultures were stained with PE-conjugated anti-CD5+ antibody and
staining evaluated by flow cytometry with 10,000 cells analyzed. Columns indicate the
mean % of cells staining for the CD5+ marker, error bars show the standard error of the

mean, and “n” indicates the number of rats evaluated.
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Figure 29. Effect of in vivo GT treatment on CD5+ splenic lymphocytes from DP/BB
rats. Treatment of DP/BB rats with GT (1 jig/g body weight, intraperitoneal injection) or
vehicle began at 30 days of age and continued until 65 days of age. Spleens were obtained

and splenocytes were recovered. Spleen cell suspensions were preincubated for 1 hour in

MEM plus 10% FCS in polystyrene flasks at 37°C in a CO2 (5%) incubator. Splenocyte
preparations were divided and half subsequently stimulated with ConA (10 jig/ml) for 1
hour. Cells were stained with PE-conjugated anti-CD5+ antibody and staining evaluated
by flow cytometry with 10,000 cells analyzed. Columns indicate the mean % of cells
staining for the CD5+ marker, error bars show the standard error of the mean, and

indicates the number of rats evaluated.
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Figure 30. Effect of GT on CD8+ DP/BB rat splenic lymphocytes exposed to GT in
vitro. Spleen cells from 65 day old DP/BB rats were obtained and preincubated for 1 hour
at 37°C in MEM plus 10% FCS in polystyrene flasks in a CO2 (5%) incubator. Cultures
were divided into four aliquots. Two aliquots were treated with GT (1 pg/ml) for 1 hour
at 37°C in a CO2 (5%) incubator and one GT treated aliquot was subsequently incubated
with ConA (10 pg/ml) for 1 hour at 37°C in a CO2 (5%) incubator.

The other two

aliquots were GT untreated controls. One was stimulated with ConA and the other served
as unstimulated controls. Cultures were stained with FITC-conjugated anti-CD8 antibody

and staining evaluated by flow cytometry with 10,000 cells analyzed. Columns indicate
the mean % of cells staining for the CD8 marker, error bars show the standard error of the

mean, and “n” indicates the number of rats evaluated.
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Figure 31. Effect of in vivo GT treatment on splenic CD8+ splenic lymphocytes from

DP/BB rats. Treatment of DP/BB rats with GT (1 pg/g body weight, intraperitoneal

injection) or vehicle began at 30 days of age and continued until 65 days of age. Spleens
were obtained and splenocytes recovered. Spleen cell suspensions were preincubated for

1 hour in MEM plus 10% FCS in polystyrene flasks at 37°C in a CO2 (5%) incubator.
Splenocyte preparations were divided and half subsequently stimulated with ConA (10
pg/ml) for 1 hour.

Cells were stained with FITC-conjugated anti-CD8 antibody and

staining evaluated by flow cytometry with 10,000 cells analyzed. Columns indicate the

mean % of cells staining for the CD8 marker, error bars show the standard error of the
mean, and “n” indicates the number of rats evaluated.
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the relative abundance of CD4+ T cells among splenic lymphocytes exposed to GT or rats

treated with GT.
The in vitro study involved incubation of splenic lymphocyte suspensions with GT.
After 1 hour of exposure to GT, aliquots of the lymphocytes were either stimulated with

ConA (10ng/ml) or remained unstimulated. The lymphocytes were labeled with PE con
jugated anti CD4 mAb and were measured by flow cytometry.

As shown in Figure 32, GT treated lymphocytes contained fewer CD4+ T cells than

did untreated controls. ConA enhanced the difference between GT treated lymphocytes
and GT untreated controls. Control cells not treated with GT had more than twice the

percentage of CD4+ T lymphocytes as GT treated cell suspensions. When GT was ad-

ministered chronically to DP/BB rats, no clear effect of GT on splenic CD4+ populations
was found and ConA did not affect this relationship (Figure 33).

RT6+ lymphocytes

The RT6+ lymphocyte subset is of critical importance to EDDM. Protocols that
can restore the RT6+ subset in DP/BB rats would be expected have a beneficial effect on
IDDM, although most investigators view restoration of RT6’ cells in DP/BB rats as a

highly improbable outcome among tested interventions.
Evaluation of RT6 cells was conducted according to both in vitro and in vivo

protocols as with other spleen cell phenotypic markers. As described in detail in the
methods section, RT6 cell staining was measured by fluorescent intensity rather than by

cell number. This technique was required by the lack of a distinct RT6 cell population that
could be separated from non-staining lymphocytes. The amount of RT6 staining was sig-
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Figure 32. Effect of GT on CD4+ DP/BB rat splenic lymphocytes exposed to GT in

vitro. Spleen cells from 65 day old DP/BB rats were obtained and preincubated for 1 hour
at 37°C in MEM plus 10% FCS in polystyrene flasks in a CO2 (5%) incubator. Cultures

were divided into 4 aliquots, and 2 aliquots were treated with GT (1 pg/ml) for 1 hour at

37°C in a CO2 (5%) incubator and one GT treated aliquot was subsequently incubated
with ConA (10 pg/ml) for 1 hour at 37°C in a CO2 (5%) incubator. Half of the non-GT

treated control cells were also stimulated with ConA and the remainder served as
unstimulated controls. Cultures were stained with PE-conjugated anti-CD4 antibody and

staining evaluated by flow cytometry with 10,000 cells analyzed. Columns indicate the
mean % of cells staining for the CD4 marker, error bars show the standard error of the

mean, and “n” indicates the number of rats evaluated.
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Figure 33. Effect of in vivo GT treatment on CD4+ splenic lymphocytes from DP/BB
rats. Treatment of DP/BB rats with GT (1 pg/g body weight, intraperitoneal injection) or
vehicle began at 30 days of age and continued until 65 days of age. Spleens were obtained

and splenocytes were recovered. Spleen cell suspensions were preincubated for 1 hour in

MEM plus 10% FCS in polystyrene flasks at 37°C in a CO2 (5%) incubator. Splenocyte
preparations were divided and half subsequently stimulated with ConA (10 pg/ml) for 1

hour. Cells were stained with PE-conjugated anti-CD4 antibody and staining evaluated by
flow cytometry with 10,000 cells analyzed. Columns indicate the mean % of cells staining

for the CD4 marker, error bars show the standard error of the mean, and “n” indicates the
number of rats evaluated.
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nificantly increased among cell suspensions treated with GT (Figure 34) and while ConA

did not enhance this difference, the difference remained significant for ConA treated cell
suspensions.

For the study of RT6 in vivo, rats received GT injections or control injections as

described previously. Analyses were done as for the in vitro study. As shown in Figure
35, the mean RT6 staining index was 1.156 in GT treated samples and 0.856 in GT un

treated controls, a difference which was statistically significant.

ConA treatment did not

eliminate this significant effect.

Summary of GT effect on spleen cells
Several different lymphocyte phenotypes were analyzed by flow cytometry with a

number of significant findings among cells treated in vitro (Table 6). Fewer phenotypes
were detectably affected when GT was used to treat the intact animals (Table 6). MHC II

data suggest GT may have a significant effect on certain APC cells. The effector NK cells
did not seem to bear an important relationship to GT treatment. However, the critically
important regulatory RT6+ cells were affected in vivo and in vitro and the relationship of

CD4* and CD8* cells was altered in vitro.

Pancreatic lymphocytes
Although the immunologic effects of diabetes may be reflected by all peripheral

sites, the actual damage occurs in the pancreas. We attempted to identify effects of GT
treatment on pancreatic lymphocytes through immunohistochemical staining. The results

were uniformly negative (data not shown), which may have been the result of using pre
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Figure 34.

Effect of GT on RT6 expression in DP/BB rat splenic lymphocytes.

Spleen cells from 65 day old DP/BB rats were obtained and preincubated for 1 hour at

37°C in MEM plus 10% FCS in polystyrene flasks in a CO2 (5%) incubator. Cultures
were divided into 4 aliquots, and 2 aliquots were treated with GT (1 pg/ml) for 1 hour at

37°C in a CO2 (5%) incubator and one GT treated aliquot was subsequently incubated

with ConA (10 p.g/ml) for 1 hour at 37°C in a CO2 (5%) incubator. Half of the non-GT
treated control cells were also stimulated with ConA and the remainder served as

unstimulated controls. Cultures were stained with unlabeled anti-RT6 primary antibody,

then FITC-conjugated anti-mouse IgG secondary antibody. The staining was evaluated by
flow cytometry with 10,000 cells analyzed and plotted as a histogram as described in the

methods section. Histogram data were converted to mean channel index shown by the
bars. Error bars show the standard error of the mean; and “n” indicates the number of rats
evaluated.
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Figure 35. Effect of in vivo GT treatment on RT6 expression from DP/BB rats.
Treatment of DP/BB rats with GT (1 pg/g body weight, intraperitoneal injection) or

vehicle began at 30 days of age and continued until 65 days of age. Spleens were obtained
and splenocytes were recovered. Spleen cell suspensions were preincubated for 1 hour in
MEM plus 10% FCS in polystyrene flasks at 37°C in a CO2 (5%) incubator. Splenocyte

preparations were divided and half subsequently stimulated with ConA (10 pg/ml) for 1
hour. Cells were stained with unlabeled anti-RT6 primary antibody, then FITC-conjugated

anti-mouse IgG secondary antibody. The staining was evaluated by flow cytometry with

10,000 cells analyzed and plotted as a histogram as described in the methods section.

Histogram data were converted to mean channel index show by the bars. Error bars show
the standard error of the mean, and “n” indicates the number of rats evaluated.
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Table 6: Summary of GT effects on spleen cells
Splenocytes of DP/BB rats

In vitro GT treated

Spleen cell
population

ConA -

MHC IF

I

NK

T

ConA +

In vivo GT treated

ConA -

ConA +

NA

NA

T

T

CD5"

CD8+

T

?

T

T

CD4+

RT6+f

* The data is significantly higher (T) or lower (J<) than its GT untreated controls,
or is not different (<->) from its GT untreated controls.

t Intensity of RT6 staining was measured by mean channel index.

NA: Data is not available.
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diabetic animals in which lymphocytic infiltration was at a minimum. We were confident

1

I

that the methods used for immunohistochemistry were not faulty since we could identify
CD8+ and RT6’ cells in spleens of normal animals.

I

I

Mechanism of Gliotoxin in Immunomodulation
Proliferation analysis
The immune response is influenced by the opposing activities of proliferation and

apoptosis. GT could exert its effects on IDDM by causing proliferation of beneficial cells
such as cell subsets that, suppress the autoimmune reaction. We studied the effect of GT
on proliferation of DP/BB rat splenic lymphocytes with and without additional stimulation
by ConA. Alamar blue was to used measure metabolic activity and to indirectly reveal cell

proliferation in vitro.
As in earlier experiments, for the in vitro arm of the studies, lymphocytes were

isolated from spleens of 65 day old, nondiabetic DP/BB rats. The lymphocytes were di
vided into 2 aliquots and incubated with GT or vehicle (ethanol) in tissue culture flasks.
Samples were further divided and stimulated with ConA (10 pg/ml) or were not treated

with ConA. As shown in Figure 36, GT reduced leukocyte metabolic activity to a very
low level even with ConA addition, suggesting that the effect of GT on IDDM probably
did not result from clonal expansion.

Although GT decreased metabolic activity of ConA treated cells, we calculated a
stimulation index to determine if the level of ConA stimulation was greater or smaller in

GT treated cell suspensions. The mean stimulation index was 1.07 in untreated controls
meaning that ConA produced 7% greater Alamar Blue reducing activity above that seen
128
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Figure 36. Effect of GT on metabolism of DP/BB rat splenic lymphocytes exposed to
GT in vitro. Spleen cells from 65 day old DP/BB rats were obtained and preincubated for
1 hour at 37°C in MEM plus 10% FCS in polystyrene flasks in a CO2 (5%) incubator.

Cultures were divided into four aliquots. The first aliquot of cells (105 cells per well) was
incubated in triplicate in a 96-well microtiter plate with GT (1 pg/ml). The second aliquot

was incubated without GT. The third aliquot was incubated with both GT and ConA (10
pg/ml).

The fourth aliquot was incubated without GT but with ConA.

The redox

indicating dye, Alamar Blue was added to each well. The color changes of Alamar Blue
were measured by a microplate reader at 590 nm after 72 hours at 37°C in a CO2 (5%)

incubator. The columns indicate the mean value of absorbance for the metabolic activities;

error bars show the standard error of the mean; and “n” indicates the number of rats
evaluated.
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without ConA addition (Figure 37). GT treated lymphocytes produced a stimulation in

dex of 0.8 indicating ConA treated cells exposed to GT showed less metabolic activity

than when ConA was absent. This finding is interesting in that it suggests that GT treated
cells may have lost responsiveness to ConA.

When the in vivo arm of the studies was performed, no significant effects on the
proliferation of cells from GT treated rats compared to vehicle treated rats was found

(Figure 38). With ConA stimulation (Figure 38, lower panel), mean absorbances of GT

treated samples and controls were similar. The stimulation index (Figure 39) for this data
did not reveal a significant augmentation of proliferative responses due to ConA

Apoptosis analysis

Because one of the key mechanisms of immune system control is selective elimina

tion of cells through programmed cell death, we investigated apoptosis as a possible
mechanism of GT in IDDM prevention. The level of apoptosis was studied both in cells
derived from GT treated animals and from untreated animals whose spleen cells were
treated with GT in vitro.
As noted in the methods, the TUNEL staining procedure was used to detect

apoptotic cells and these were enumerated by flow cytometry. The apoptosis of DP/BB
rat lymphocytes was also studied with or without ConA stimulation since apoptosis may

be enhanced or suppressed when superimposed on cytokine production, receptor expres

sion and T cell proliferation.

Apoptosis was measured in spleen cells from DP/BB rats treated in vitro with GT
compared to untreated cells. As shown in Figure 40 (upper panel), GT treated DP/BB rat
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Figure 37. Effect of GT on proliferation of in vitro GT treated DP/BB rat splenic
lymphocytes. From the data presented in Figure 36, a stimulation index was calculated to

quantify the influence of ConA on the splenic lymphocytes.

The stimulation index is

Alamar Blue reduction (A59o) with ConA divided by Alamar Blue reduction without
ConA. The columns indicate the mean value of proliferation; error bars show the standard

error of the mean; and “n” indicates the number of rats evaluated.
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Figure 38. Effect of GT on metabolism of DP/BB rat splenic lymphocytes. Treatment
of DP/BB rats with GT (1 |ig/g body weight, intraperitoneal injection) or vehicle began at
30 days of age and continued until 65 days of age. Spleens were obtained and splenocytes

recovered. Spleen cell suspensions were preincubated for 1 hour in MEM plus 10% FCS

in polystyrene flasks at 37°C in a CO2 (5%) incubator. Cells from GT or control rats were
each divided into two aliquots. The first aliquot of cells (105 cells per well) was incubated
in triplicate in a 96-well microtiter plate with ConA (10 pg/ml). The second aliquot was

incubated without ConA. The redox indicating dye, Alamar Blue was added to each well
and incubated for 72 hours at 37°C in a CO2 (5%) incubator.

The color changes of

Alamar Blue were measured by a microplate reader at 590 nm. The columns indicate the

mean value of absorbance for the metabolic activities; error bars show the standard error
of the mean; and “n” indicates the number of rats evaluated.
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Figure 39. Effect on proliferation of splenic lymphocytes from in vivo GT treated

DP/BB rat. From the data presented in Figure 38, a stimulation index was calculated to

quantify the influence of ConA on the splenic lymphocytes.

The stimulation index is

Alamar Blue reduction (A590) with ConA divided by Alamar Blue reduction without

ConA. The columns indicate the mean proliferation; error bars show the standard error of
the mean; and “n” indicates the number of rats evaluated.
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Figure 40. Effect of GT on apoptosis of DP/BB rat splenic lymphocytes. Spleen cells

from 65 day old DP/BB rats were obtained and preincubated for 1 hour at 37°C in MEM

plus 10% FCS in polystyrene flasks in a CO2 (5%) incubator. Cultures were divided into
4 aliquots, and 2 aliquots were treated with GT (1 pg/ml) for 1 hour at 37°C in a CO2

(5%) incubator and one GT treated aliquot was subsequently incubated with ConA (10
pg/ml) for 1 hour at 37°C in a CO2 (5%) incubator. Half of the non-GT treated control

cells were also stimulated with ConA and the remainder served as unstimulated controls.
Cultures were stained with the TUNEL method as described in the methods section. The

FITC staining of apoptotic cells was determined by flow cytometry with 10,000 cells
analyzed. The columns indicate the mean % of cells staining for apoptosis; error bars

show the standard error of the mean; and “n” indicates the number of rats evaluated.
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splenic lymphocytes showed 23.6% apoptosis, a level significantly higher than the 6.0%

seen in untreated controls. When repeated with ConA stimulation, this same experiment
showed a four-fold difference (Figure 40, lower panel) as it did without ConA (P<0.01).

In vivo GT treatment provided results which were not as pronounced as for in vi
tro GT treatment. Splenic lymphocytes from GT treated rats showed 15.67% apoptotic
cells while 7.50% of cells from untreated controls were apoptotic (Figure 41, upper
panel), and ConA stimulation of lymphocytes recovered from GT treated or control rats

showed a significant difference in apoptosis levels, with 6.3% of splenic lymphocytes from
GT treated DP/BB rats apoptotic and 2.6% of untreated controls apoptotic (Figure 41,
lower panel).
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Figure 41. Apoptosis of splenic lymphocytes from in vivo GT treated or control

DP/BB rats. Treatment of DP/BB rats with GT (1 pg/g body weight, intraperitoneal

injection) or vehicle began at 30 days of age and continued until 65 days of age. Spleens
were obtained and splenocytes were recovered.

Spleen cell suspensions were

preincubated for 1 hour in MEM plus 10% FCS in polystyrene flasks at 37°C in a CO2

(5%) incubator. Splenocyte preparations were divided and half subsequently stimulated
with ConA (10 pg/ml) for 1 hour.

Cells were stained with the TUNEL method as

described in the method section to determine the apoptotic cell percentage in splenic
lymphocytes. The FITC staining of apoptotic cells was evaluated by flow cytometry with
10,000 cells analyzed.

The columns indicate the mean % of cells staining for the

apoptosis; error bars show the standard error of the mean; and “n” indicates the number of
rats evaluated.
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DISCUSSION

Although various methods and reagents intended to lessen the effects of IDDM
have been studied, none of them has proved ideal in IDDM prevention and/or treatment.

The research presented in this dissertation summarizes our efforts to evaluate an immu
nomodulator, GT, as a potential preventive for use in averting IDDM development. Pre
vious work in our laboratory showed that the yeast Candida albicans produces GT which

may inhibit host immune responses, allowing yeast infection in the human vaginal tract to
persist without immune elimination. Although our current understanding of GT as an im
mune response modifier is limited to its effects on PMN’s, the discovery of its action on

white blood cells led us to hypothesize that GT may prevent IDDM in DP/BB rats. We

also hypothesized that GT exerts selective immunosuppressive activities which may distin
guish it from other immunosuppressive fungal products, such as CsA. GT may have spe
cific effects in certain cell types rather than global functions directed toward all immune

cell types as CsA does. Such selectivity would serve as an important innovation in im
munosuppressive chemotherapy.

The present investigation provided three major findings. First we demonstrated
that GT treatment of diabetes prone animals successfully delayed onset of IDDM. To our
knowledge, this is the first study that shows the effectiveness of GT in interrupting auto
immune pathogenesis. Further emphasizing its effectiveness, we found that GT treatment

decreased blood glucose levels in pre-diabetic DP/BB rats. Second, GT selectively influ

ences several regulatory T cell subsets without causing the same reaction among all lym
phocyte subpopulations, which is important because the clinical promise of immune
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modulator therapy requires selective rather than universal immunosuppression. Third, GT
induces lymphocyte apoptosis which provides an explanation of how GT may exert its ef

fect on the immune system. These three findings, coupled with the demonstration that GT

has limited systemic toxicity in the animal model studied, provides important insights into
GT and its immunomodulating function in relation to autoimmunity inhibition, and further
indicates that GT could have future potential in human disease. This new knowledge may

help provide better understanding of EDDM both scientifically and clinically.

Limited systemic toxicity of GT

Before undertaking studies of diabetes prevention it was necessary to evaluate GT

toxicity. It was not the intention of this project to perform a complete toxicologic investi

gation, but rather we limited our study to experiments that would suffice to allow prelimi

nary animal studies. We first exposed an insulin-secreting 0 cell line, RIN 38 insulinoma
cells, to GT at various concentrations and determined the viability and insulin secreting

ability of these cells following GT challenge. GT treatment did not alter the viability of
RIN 38 cells at concentrations of 1 jig/ml or less and while some effect (28% reduction)

on insulin secretion was seen at 1 pg/ml GT concentration, insulin secretion was not seri
ously compromised. We also noted that the rate of body weight gain during GT treatment

of DP/BB rats (from age 30 days to 65 days) was normal. Leukocyte counts after 10 GT

injections over a 24 day period failed to elicit leukopenia. Finally, liver and kidney his
tologic sections of GT treated animals were essentially indistinguishable from those of

control DP/BB rats which had not been exposed to chronic GT treatment. These results
gave us confidence that GT at a dosage of 1 pg GT per gram body weight is not too toxic
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for use in these experimental animals. In fact, when we treated DP/BB rats with GT at

this dosage, GT showed a truly salutary biologic effect in terms of diabetes prevention, but
the experimental animals remained overtly healthy during prolonged observation.

Delayed onset of IDDM by GT

When GT treatment of DP/BB rats was started at 30 days of age and continued to

120 days of age, GT treated animals showed an average of diabetes onset of 98 days com
pared to 82 days average age of onset among the control rats. This finding coupled with
the incidence of 90% diabetes within 120 days among control rats versus 55% incidence
among GT-treated animals proved significant by life-table analysis.

Although the GT

treatment study demonstrated that GT is able to influence the development of autoimmu

nity, to achieve its beneficial effects the GT treatment had to start at 30 days of age. GT
treatment begun at 40 days was not effective in diabetes prevention.

The reason GT

treatment is effective when started at 30 days of age but not at 40 days of age may relate

to the existence of different phases of autoimmune pathogenesis. In autoimmunity one can
envision two stages, an early stage in which autoimmune cells are generated and a late

stage in which autoimmune damage occurs, driven by effector cells such as macrophages,
NK cells or CTLs. The finding that the intervention is effective at 30 days, but not 40
days, suggests that GT may be influencing the early stages of autoimmunity rather than the

late, effector phase. This issue will be discussed again in greater detail when the cell types

affected by GT are considered. Interestingly, our findings are consistent with other studies
in that several investigators have identified a window of intervention opportunity which

may relate to some critical milestone in lymphatic system maturation. Gottlieb and Rossini
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(1993) called this phenomenon the “window of vulnerability” during which time immune

interventions to prevent IDDM in DP/BB rats may be effective. In this window period,

autoimmune processes are not fully established and effector cells are minimally active al
lowing immune interventions to change the course of IDDM. When the window is closed,
the effector phase is fully active and the immunoregulatory phase is matured so that most

immune interventions are no longer effective.
Complementing its effect on disease incidence, we also found that GT treatment
significantly reduced blood glucose levels among both diabetic and prediabetic rats. The

reason why GT lowered blood glucose levels was not directly investigated as part of this

study, but the observation is consistent with a preservation of P cell function. Serum glu
cose is controlled by various metabolic hormonal factors, but primarily through reciprocal
interaction of insulin and glucagon. Insulin is produced by the P cells of the islets of

Langerhans in the pancreas. The signals for the release of insulin from the P cells are a

high blood sugar level and, to a lesser extent, high plasma levels of some amino acids.

The release of insulin in response to a glucose load shows two phases, an early burst of
insulin release and a later slow output of hormone. Insulin reduces cAMP levels, probably
by speeding up the destruction of cAMP by phosphodiesterase. Insulin suppresses glu

coneogenesis and at the same time increases glycolysis. Glucagon has activity that op
poses insulin and can increase gluconeogenesis by increasing synthesis of several enzymes
(Stryer, 1988). The diabetic patient is characterized by a deficiency of pancreatic islet P-

cells resulting in loss of adequate of insulin production. Glycolysis is inhibited and the
blood glucose level increases. When the glucose level reaches a critical point, the patient
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becomes diabetic and the toxicity of glucose accumulation will lead to damage of various
organs.
There are several possible explanations for reduced glucose levels among GT
treated rats. GT could increase insulin secretion, as occurs with the oral hypoglycemic

sulfonylureas, tolbutamide and tolazamide, resulting in lower blood glucose levels. This is
unlikely since studies of GT action on RIN 38 insulin secretion showed that GT did not
increase, and actually reduced somewhat, insulin production by this p cell line. Blood glu

cose could be controlled in GT treated rats because of direct protection of p cells from

autoimmune attack which would preserve insulin producing capacity. However this is not
consistent with our early study in which GT treatment started after 40 days of age is not

protective, suggesting that GT is not able to influence the effector phase of autoimmunity.
GT could also lower blood glucose through P cell regeneration. This possibility was not
supported by the RIN 38 cell studies. Another explanation for the blood glucose effects is
decreased peripheral insulin resistance. Since peripheral insulin resistance is not the main

mechanism of IDDM in DP/BB rats, this is unlikely to be the role of GT. The elimination

of these various explanations returns our focus to immunologic mechanisms. Many other
studies (Bowman, Leiter and Atkinson, 1994) on IDDM prevention using a variety of approaches also emphasizes the immunopathogenic mechanism, as well.

Therefore it is

likely that GT decreases blood glucose by preservation of P cell function by preventing or

modifying autoimmune disease.
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Selective influences of GT on regulatory T cell subsets
Published studies support GT function as an immune suppressor (Sutton, Waring

and Mullbacher, 1996; Murayama, et al 1996; Sutton, et al., 1996) which has led to its
use in prevention of transplant rejection (Sutton, et al., 1995; McMinn, Halliday and
Muller, 1990; Mullbacher, et al., 1988; Lissing, Tuch and Suranyi, 1988). Early work

from our laboratory showed that GT suppressed PMN oxidative burst in response to

stimulation by complement components (Shah, et al. 1995). In contrast, the results from
the present study demonstrated that GT induced lymphocyte apoptosis, suppressed lym

phocyte proliferation and altered the proportions of certain lymphocyte subsets. Both the

lower blood glucose levels in GT treated animals and the delay in diabetogenesis are all
likely attributable to the effects of GT on the immune system of DP/BB rats.

A key issue raised by the protective effect of GT is what parts of the immune systern is/are affected. One drawback of many immune interventions, such as CsA, is their

fairly global effects on the immune system. For various reasons, a new immunotherapy
reagent should possess a more specific function, preferably one which will prevent auto
immune disease without causing increased susceptibility to infection or cancer in drug re
cipients.

The research approach we pursued was to investigate whether GT had a demon

strable effect on lymphocyte cell subsets in experimental animals prone to diabetes. These
analyses were conducted both on isolated cells treated with GT and on animals treated

with GT. Although study of GT’s effects on isolated cells is more sensitive, investigation

of GT’s effects in vivo is essential because that is the ultimate place where GT could be
valuable, and where we demonstrated its efficacy in diabetes prevention.
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As noted earlier, diabetes preventive measures may interfere with various stages of
disease development. Thus, we investigated the MHC II cells as potential indicators of

antigen presentation, NK cells as indicators of cytotoxic effects, and CD4*, CD8" and
RT6+ T cells as indicators of an immune regulatory component of the anti-diabetic effect.
Such results must be interpreted with caution because broad categories of lymphocytes do

not completely and uniquely correlate with function. For example, NK cells function pri
marily as effectors but can also be involved in regulatory functions. CD8+ T cells can be

effectors but also regulators. Macrophages and dendritic cells are mainly APC’s, but B
cells can function as APC cells as well.
For in vitro studies, splenic cells were isolated from 65 day old prediabetic DP/BB

rats then treated with GT. For in vivo studies, splenic cells were also isolated from pre

diabetic animals at 65 days of age, however these animals were treated with GT from 30

days of age to 65 days of age. The reason prediabetic DP/BB rats were chosen for this
study was because GT was ineffective late in pathogenesis and we would envision immune

intervention occurring during the earlier prediabetic period versus later. The splenic cells

were studied under either with ConA or without ConA stimulation. ConA is the mitogen
to induce T cell proliferation and to enhance cytokine production and cytokine receptor
expression. Proliferating cells are more susceptible to drug treatment so that the effects of

GT to T cell subsets may be measured more sensitively.
One of the prevailing theories of autoimmune pathogenesis implicates faulty anti

gen presentation in development of the disease process. For this reason we investigated
GT’s effect on MHC II cells which includes APC’S. Faulty antigen presentation may display self antigens as foreign and induce autoimmunity. Antigen presentation may also
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stimulate regulatory T cell activation and enhance autoimmune pathogenesis. The activated regulatory T cells may also increase the activity and/or number of APC to further
enhance the autoimmune antigen presentation and the autoimmune process. Under these

conditions, more cells bearing MHC class II surface markers could be expected. Our ef
forts provide limited information in this area because our cell preparation methods were
not designed to maximize macrophage recovery and even if a very robust yield of macro
phage and dendritic cells had been achieved, the antigen presenting activity would need to

be evaluated in a specific manner separate from enumeration of MHC II’ cells. We did

not initially observe differences in MHC II staining among GT-treated splenic cells com
pared to non-treated cells in which lymphocytic cells were gated. This population would
have been expected to include B lymphocytes. Although B cells may present antigens,

they are probably of little consequence in the antigen presentation pertaining to IDDM.
Thus it was not surprising that MHC II staining was not affected in this evaluation. To
provide a more comprehensive evaluation, we re-gated and re-analyzed the MHC II data

to include larger cells and those with potentially greater granularity. The cells in this gate
were highly sensitive to GT, although we cannot definitively state the identity of these
cells. Because this analysis showed that at least some MHC II positive cells were elimi-

nated by GT we cannot preclude a possible effect of GT on APCs. Although GT may or

may not have an effect on APCs, we did not look for individual subsets of MHC class II
positive cells. If GT treatment only affected one subset, our methods would not have been
sensitive enough to detect such subtle differences. MHC II positive cells were used to in
vestigate antigen presentation as the step in the autoimmune process were GT has its ef

fect, and these cells were not clearly implicated.
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Evaluation of NK cells was used to investigate one of the late steps in diabeto-

genesis, namely the effector phase, either in vivo or in vitro. Enumeration of NK cells
yielded the results which is not significant different between GT treated lymphocytes and

controls. This is not surprising, since the study showing that GT treatment beginning at

40 days of age was ineffective. IF GT affects IDDM pathogenesis through NK cells, GT
treatment beginning after 40 days of age should also be effective

This implies that the

main effect of GT is earlier than the NK-dominated phase of pancreatic damage.

Having

demonstrated that the earliest (antigen-presenting) and latest phase (NK-dominated) of the

autoimmune reactions are unlikely to be the main targets of GT action, we devoted our
attention to T-cells, and in particular, the immunoregulatory aspects of the disease.
Most differences among splenic cells revealed by this study occurred in T cell

populations. The change could be within different T cell subsets.

The occurrence of

genuine changes in T cell subsets were revealed by studies of specific surface markers, the
most notable being CD4+. In addition, specific subset changes were most clearly seen

from in vitro data. Although not all effects seen in the in vitro studies were replicated in
the in vivo studies, many of the observations in vivo were qualitatively similar to those

seen in in vitro. As will be discussed in greater detail later, the in vivo studies tend to be
somewhat less sensitive in depicting the effects of GT’s on lymphocyte populations. This

may be primarily due to pharmocokinetic and pharmacodynamic considerations. Because
T cells in general are probably too broad a category to delineate GT’s effects, we focused

on CD4+ and CD8+ cells, each of which may play regulatory roles in normal and abnormal immune responses. CD4+ T cell percentage was decreased and CD8* T cell percent
age was increased in the in vitro experiments. Similar results were obtained in vivo that
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statistical significance was not attained due to the small number of animals.

Together,

such results portray GT as a selective immunotoxin or immunomodulator, a key property
for a useful immunotherapeutic drug.

Earlier studies have shown the effects of CD4 and CD8 lymphocytes in IDDM and

other autoimmune diseases. Both CD4 and CD8 T cells were required for successful

adoptive transfer of disease with diabetic spleen cells into young NOD mice (Bendelac, et

al., 1987) and irradiated adult NOD mice (Miller, et al 1988; Barey, et al., 1991), but the
relative roles of the two subsets remains controversial. CD4 T cells from donor NOD
mice were critical for diabetes development in T cell-depleted NOD mice (Hanafusa, et al.,

1988). Purified CD4 T cells from diabetic donor spleens transferred disease at low effi
ciency in immunodeficient NOD mice, although purified CD8 did not (Christianson, Shultz

and Leiter, 1993). Other studies indicated that the role of CD4 T cells in IDDM patho
genesis was to recruit CD8 T cells as final effectors in islet (3-cell destruction (Thivolet, et

al., 1991; Matsumoto, et al., 1993). As shown by a recent study by Peterson and Haskins
(1996), one CD44 T cell clone, BDC-6.9 can transfer IDDM without help from host B
cells, CD4* T cells or CD8+ T cells. A second CD4+ T cell clone, BDG-2.5 only induced

IDDM when CD8+ T cells were present. Different T cell clones require different levels of

accessory cell involvement. BDC-6.9 cells arise later in the disease process and can act
alone. DBC-2.5 may be representative of the earliest diabetogenic CD4 T cells that re
quire help from CD8 T cells, and would become an appropriate cell subset to investigate

in future studies of the effects of GT.
Collagen-induced arthritis (CIA) is a different but useful experimental autoimmune

disease elicited by immunization with type II collagen. As shown by one recent study
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(Amano, et al., 1995), CIA incidence in CD8 -/- mice was significantly decreased com

pared to the incidence among CD8 +/- mice. This result suggests a role for CD8 T cells
in initiating CIA. Interestingly, CD8 deficient mice were more susceptible to a second in

duction of arthritis after remission of initial disease, pointing toward an immunoregulatory
role for CD8" T cells (Tada, et al., 1996). CD8+ T cells have been implicated as an initial

element required to recruit CD4+ T cells to islets and may also function as a final effector

in P cell damage.
When an individual becomes diabetic, the CD4+ T cell percentage increases signifi

cantly and CD8+ T cell percentage declines slightly. A human IDDM study (Ilonen, Surcel
and Kaar, 1991) indicated that CD4+ and CD8+ T cell subsets were 38% and 27% respec
tively before diabetes and 44% and 26% after the patients developed overt diabetes. The

ratio of CD4/CD8 T cells was also increased. Since CD4’ and CD8+ T cells are important

regulatory lymphocytes, and in view of the human data mentioned, our observed decrease
in CD4" T cell numbers, and increase in CD8+ T cell numbers and a decreased CD4/CD8
T cell ratio are noteworthy as they are consistent with a beneficial effect toward IDDM.

We showed that GT treatment decreased the relative number of CD4+ T cells and in
creased the relative number of CD8' T cells, and the ratio of CD4/CD8 T cells was de

creased, although the effect was limited to in vitro observation.
In vitro GT treatment is undoubtedly more potent than in vivo treatment with respect to T cell population dynamics for several reasons. The GT concentration in vitro

remains constant and probably attains a higher local concentration. In addition, in vitro

conditions provide a constant environment, uniform cell populations and no biological

clearance mechanisms as would exist in vivo. In vivo GT treatment cannot be expected to
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be as effective as in vitro for several additional reasons. The GT dose used in BB rats was
chosen to avoid toxicity rather than maximize its biological effects. The in vivo dosage

schedule was episodic which should result in peak and trough tissue levels of GT. This

pulsatile treatment was originally intended to let animals recover somewhat after acute

exposure to GT to prevent cumulative toxicity, but we had no way to judge the therapeu
tic index (difference between diabetes protective dose and toxic dose) in these preliminary

studies. GT was injected intraperitoneally and it is unknown how much GT reaches the
spleen, pancreas and other relevant sites. Indeed, the effects seen among spleen cells
could have been generated in the bone marrow, but without specific studies, the ultimate

source of in vivo effects is difficult to predict. Our study did clearly indicate that sufficient
drug was present in vivo to prevent disease even though it may not have resulted in de

tectable effects on CD4+ and CD8’ T cells.

One of the most important advances in understanding diabetogenesis in the DP/BB
rat has been the discovery of the RT6+ marker on mature lymphocytes. Because of its sig

nificance in the DP/BB rat, we focused attention on this lymphocyte subset which is nearly
absent in DP/BB rats and is highly associated with diabetes incidence. RT6 protein is not

totally absent from DP/BB animals and is detected at a very low level on a small number
of cells. Explanations for the RT6+ T cell subset deficiency include premature cell death

and gene regulation defects. RT6 in normal rats is present on mature cells and death of
these cells prior to full maturation could lead to low numbers of RT6+ cells. Alternatively,
failure of cells destined to become RT6+ to produce adequate quantities of RT6+ surface

antigen could also be responsible for low levels of RT6. Although GT treatment did not
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restore RT6* cells to normal levels in DP/BB rats, treatment did increase RT6 surface
marker detection both in vivo and in vitro.

Several previous investigations have underscored the importance of the RT6 sur
face marker among DP/BB rats in contrast to DR/BB rats, WF rats and LEW rats at dif-

ferent ages. Neither RT6.1 nor RT6.2 was found on DP/BB rat T cells, but they were
found on T cells of other rats (Greiner, et al. 1986). A soluble form of RT6 rat lymphocyte
alloantigen was detected in serum of DP/BB, DR/BB and WF rats by Western blot analy
sis, but DP/BB rats circulated less RT6 alloantigen than did DR/BB or WF rats (Waite, et

al. 1993). Anti RT6.1 mAb injection into DR/BB rats depleted >95% of peripheral RT6 T

cells, but did not reduce levels of circulating T cells or the in vitro response of spleen cells
to mitogen. If this treatment was started at 30 days of age, it significantly enhanced the

frequency of diabetes in DR/BB rats. If anti-RT6 antibody treatment was started at 60
days of age, it failed to produce these effects (Greiner, et al. 1987).
The immunoregulatory function of the RT6* T cell subset has been confirmed by

many studies but the reason for the absence of RT6 surface marker in DP/BB rats was in
vestigated by Crisa, et al (1993). They discovered that an mRNA encoding RT6 protein
was present in spleen cells of diabetes-prone rats and the nucleotide sequence of this tran

script revealed an intact coding region for the RT6 alloantigen. In addition, RT6 mRNA
was translated in vivo, but the RT6 protein in DP/BB rat lymphocytes was less than 10%

of the amount found on DR/BB rat lymphocytes. The intact phosphatidylinositol linkage
of the molecule to the cell surface was detected in DP/BB rat lymphocytes by immunopre
cipitation. These investigators concluded that defects in RT6 gene regulation or other
cellular defects leading to premature cell death were operative in these animals.
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Because the effect of GT on RT6 was more subtle than its effects on such cell

populations as CD4’ T cells, a different method of analysis was applied to RT6 data. The
mean channel number is a measurement derived from flow cytometry evaluation in which

the average fluorescent intensity of a cell population is recorded. RT6" T cell staining was
measured by this method because a distinct population of intensely stained cells was not

present in splenocytes recovered from DP/BB rats.

Crisa et al (1993) indicated that RT6 protein expressed is reduced in DP/BB rats

and altered RT6 gene regulatory mechanisms may be responsible for RT6 deficiency. We
detected higher anti-RT6 immunofluorescent staining in GT treated splenic lymphocytes
which may result from enhanced expression ofRT6 protein on the surface of lymphocytes

after exposure to GT, although direct investigation of RT6 protein levels would be appro
priate to verify this explanation. After gene transcription, a series of enzymes and regula
tory proteins are involved in translation, modification and protein targeting. Synthesized

protein will fail to be expressed on membranes if any of these enzyme and regulatory pro

teins are non-functional. GT may bind the defective enzyme or regulatory protein to improve its function, leading to greater RT6 protein expression. Known characteristics of
GT support the possible interaction with biologically active proteins. GT is a small hydro
phobic molecule which passes through cell membranes. The disulfide group of GT can
bind similar groups on regulatory proteins to modify their regulatory functions. Although

RT6" T cells were not restored to levels comparable to those seen in DR/BB and other

normal* rats, more RT6 protein on the lymphocyte surface was observed which may in
crease immunoregulatory function which in turn results in decreased p cell loss.
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We can not exclude the possibility that GT prevents early death of RT6+ T lym
phocytes based on the information from this study. But the flow cytometry data contro-

verts the “early death” explanation. If RT6+ T cells die earlier in the absence of GT and
this is the only reason the RT6+ T cell subset is missing, the RT6 surface marker should be

expressed at normal levels on each individual cell even though those RT6+ cells will be

present only in small number. Prevention of early death should restore the RT6* cell
population. If this were to occur, flow cytometric data would be expected to show a

separate dot group corresponding to cells with normal amounts of surface RT6 protein.
Our results, however, show increased RT6 staining but not a separate RT6’ population.

This result is more indicative of greater RT6 expression than greater RT6* cell survival.
This interpretation suggests that future studies should more directly determine if GT

treatment intervenes in an intracellular regulatory mechanism of RT6 protein synthesis
acting on signal transduction, synthesis, modification and trafficking.
Together, analysis of cell populations (CD4, CD8 and RT6) show that GT is func

tional as an immunomodulator and that its effects are not global. The inhibitory effects of

GT are more potent with respect to some cell types and less potent toward others. The
effect of RT6 may prove to be even more selective than our results show since we did not

distinguish between various subsets of CD4 or subsets of CD8+ T cells. CD4' or CD8~ T
cells include clones with different antigen specificity and different functional characteris

tics. Although CD8+ cells are often noted for containing CTL, a recent study indicated

that one CD8+ T cell subset is not cytotoxic and is protective with respect to autoimmune
disease. Studies on particular CD4+ and CD8+ T cell subsets should be evaluated in future

studies to provide a more comprehensive understanding of GT’s action.
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Since it is now recognized that most immunologic functions are controlled by cy
tokines, additional areas for further investigation involve cytokine functions which have

been linked with IDDM pathogenesis and modulation by GT. Helper T lymphocytes (Th)

(mostly CD4") and cytotoxic T lymphocytes (Tc) (mostly CD8 ) are characterized by par
ticular patterns of cytokine production. These patterns, distinguish Thl from Th2 among

helper T cells and Tel from Tc2 among cytotoxic T cells. Thl and Tel T cells produce
IL-2 and IFN-y which appear to be positively related to IDDM. Th2 and Tc2 T cells pro-

duce IL-4, IL-5 and IL-10 which inhibit IDDM (Mosmadd and Sad, 1996). Some evi-

dence from the present study may indirectly link GT function to cytokine production. For

example, ConA stimulation, which elicits cytokine secretion, enhanced GT-induced apoptosis. The difference in CD8+ T cell percentage between GT treated lymphocytes and

controls was widened by ConA stimulation. GT treatment may enhance production and
function of IDDM-preventive cytokines and inhibit IDDM-promoting cytokines. This re-

lationship may be investigated in vitro and in vivo as appropriate rat anti-cytokine probes
become available.

Lymphocyte apoptosis induction by GT

There are three possible reasons to explain the observed changes among T cells.
These include lymphopoiesis, selective proliferation of T-cell clones and toxic effects on
specific clones. We measured peripheral leukocytes and saw no obvious alteration that
was suggested an effect on lymphopoesis. Our proliferation test results showed that GT

did significantly inhibit lymphocyte metabolism in vitro and this effect was not overcome
by the mitogen, ConA. In vivo GT treated cells failed to show a significant response to
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ConA raising the question of whether GT blocked persistently the proliferation ability of

these cells. Perhaps, more notable is the finding that GT can induce apoptosis of lympho
cytes both in vitro and in vivo. This provides a possible explanation for GT induced de

creases in CD4+ T cell percentage and emphasizes lymphocyte elimination as a likely ex
planation of the observed changes in T cell subsets.

Some reports in the literature indicate that GT induces apoptosis in different cell
types in the immune system, including macrophages (Waring, 1990; Waring, et al., 1988),
splenic lymphocytes (Braithwaite, et al., 1987) and T blast cells (Waring, et al., 1990).
i

i

GT also triggers cell surface receptors and enhances lymphocyte activation (Sutton,
1995). The present investigation represents the only report which shows that GT can en-

hance lymphocyte apoptosis both in vivo and in vitro.

Apoptosis is an important mechanism by which the immune system eliminates
harmful cells and controls its immune responses. Although several apoptosis mechanisms

have been studied, Fas and Fas ligand interaction is considered among the most important
for T lymphocyte apoptosis. Normally, antigen presenting cells express self antigen as a
complex with MHC. This complex interacts with T cell receptors on autoreactive T cells

to activate them. Activation of these T cells induces Fas and Fas ligand gene expression.
T cell-T cell interaction will then cause elimination of harmful T cells through Fas ligand

binding to its cognate receptor (Thomas, et al., 1995) thereby preventing development of
autoimmune disease.
At present we do not know the precise mechanism whereby GT promotes apopto
sis. GT may activate certain types of T lymphocytes through triggering of surface receptors. This T cell activation could increase Fas and Fas ligand expression and enhance
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apoptosis. The second possibility is that GT directly binds Fas protein on the T cell sur
face, thereby triggering Fas receptor as Fas ligand normally would, resulting in apoptosis
of target T cells. Finally, it is also possible that GT, which is relatively hydrophobic,
passes through the lymphocyte cell membrane and binds specific cellular components. The

disulfide group of GT may bind sulfhydyl or disulfide groups on target proteins. If these
GT-binding proteins are involved in regulating the cellular processes, such GT-protein in-

teractions could enhance apoptosis (Waring, et al, 1994). Because ConA stimulation,

which enhances surface receptor production, widened the differences in apoptosis among

GT treated compared to untreated cells, a direct triggering of Fas receptors by GT seems
possible. This concept will require additional investigation to confirm this proposed role

for GT.

Because GT induced apoptosis and altered the relative abundance of certain lym
phocyte subsets, we inferred that apoptosis induction could account for T cell subset

change. To verify that apoptosis is the mechanism for changing cell subpopulations we

would need to demonstrate that apoptosis occurs in the same subsets of cells that we

found to be decreased by GT treatment. The drawback to using the current TUNEL
method is that ethanol permeabilization of the cells is incompatible with immunophenotyping because of denaturation of cellular epitopes. An alternative protocol has become

available that provides the ability to directly probe apoptosis and simultaneously stain

surface markers such as CD4* or CD8+. This method avoids ethanol use which may di
minish mAb interaction with corresponding surface markers.
Before leaving the discussion of the influences of GT on various categories of
lymphocytes, we must note that the immunologic damage of IDDM takes place in the
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pancreas, although several reports have indicated that central immune defects are trans

ported to the periphery in BB rats. Attempts to document pancreatic changes, in particu
lar changes of lymphocytes in pancreatic islets, were unproductive. In retrospect, because

we conducted these studies in very early prediabetic animals, there may have been little or
no lymphocytosis of the islets. A more useful method for approaching the issue of GT’s

effects on pancreatic lymphocytes would be to use older BB rats or to use NOD mice in
which insulitis develops more chronically than it does in BB rats. The lack of definitive

results from pancreatic tissue, however, does not diminish the value of observations made
on splenic lymphocytes.

The work presented has shown that GT treatment is effective in IDDM prevention

in DP/BB rats, presumably through selective immune function modifications. GT may

have promise as protective treatment to prevent human IDDM, although GT has not yet
been studied in human subjects. Perhaps in vitro studies of human cells would be an ap

propriate first step in moving toward human therapy. The ultimate goal from such investi
gation would be human IDDM prevention; a goal which appears reasonable in view of the

positive findings in this research.
The results presented portray GT as a compound with potential for continued de

velopment as an immunopharmacologic agent for use in autoimmune diseases. We recog
nize that GT may function in IDDM prevention through apoptosis induction, thereby po
tentially affecting regulatory lymphocytes. This raises the issue of risk involved in devel

oping Gt or a similar compound for use in humans. GT did not show a serious toxicity to
experimental DP/BB rats as seen in their general physical condition, histology and blood
counts from treated animals. The potential value of GT as a new drug to prevent IDDM
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may be rationally considered after requisite phamacology and toxicology studies are com
pleted.

In speculating on the future potential of GT, the best example for comparison is
CsA. CsA has been studied as a diabetes prevention drug. CsA is a nonspecific immuno

suppresive drug which inhibits T lymphocyte activation, cytokine production, and even

apoptosis. In contrast to CsA, GT, while having immunosuppressive properties, appears
selective, may induce T cell activation of some cell populations and induce lymphocyte

apoptosis of some cell populations. CsA interacts with cyclophilin, a 17 kDa protein that
possesses peptidyl-prolyl cis-trans isomerase (PPIase) activity. This interaction acts by

means of blockage of signal transduction. GT has a disulfide group which may bind to as
yet unknown intracellular target proteins or trigger cell surface receptors to stimulate sig

nal transduction. CsA has nephrotoxicity, manifested by decreased glomerular filtration
rates, associated with a reduction in renal blood flow that reflects an increase in vascular
resistance. GT showed little potential for kidney damage in our limited histologic studies.

Although CsA inhibits autoimmuntity in several animal models, its toxicity currently limits

its long term use. Our findings indicate that GT or a congener of GT, with appropriate
pharmaceutical development, may be found to be a good alternative to CsA to intervene in

cases of EDDM and other autoimmune diseases.
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LIST OF ABBREVIATIONS
APC

antigen presenting cell

Apo

cell surface protein (apoptosis)

BB rat

BioBreeding rat

BSA

bovine serum albumin

CD

cluster of differentiation

CDR

complementary-determining region

CIA

collagen induced arthritis

ConA

concanavalin A

CsA

cyclosporin

CTL

cytotoxic T lymphocyte

DP/BB rat

diabetes prone/BioBreeding rat

DR/BB rat

diabetes resistant/BioBreeding rat

ETP

epipolythiodioxopiperazine

FACS

fluorescence-activated cell sorting

Fas

name of cell surface protein family

FBS

fetal buvine serum

FITC

fluorescein isothiocyanate

FSC

forward scatter

GAD

glutamic acid decarboxylase

gid

a gene name

GT

gliotoxin
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GVHD

graft vs. host disease

H&E staining

hematoxylin and Eosin staining

HLA

human leukocyte antigen

IA-2

islet antigen-2

ICA

islet cell antigen

IDDM

insulin dependent diabetes mellitus

IFN

interferon

Ig

immunoglobulin

IL

interleukin

KRB

Krebs-ringer buffer

LCM virus

lymphocytic choriomeningitis virus

Ipr

gene involved in lyphoproliferation

mAb

monoclonal antibody

MEM

minimum essential medium

MHC

major histocompatibility complex

NK cell

natural killer cell

NOD mouse

non-obese diabetic mouse

PBS

phosphate buffered saline

PE

phycoerythrin

PGO

peroxidase-glucose oxidase

PI

propidium iodide

PKC

protein kinase C
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PMN

polymorphonuclear leukocyte

PTP

protein tyrosine phosphatase

RIA

radioimmunoassay

RT6

a prepheral lymphocyte curface marker

SI

stimulation index

SLE

systemic lupus erythematosus

src family

name of gene family

ssc

side scatter

Tc

cytotoxic T cell

TCR

T cell receptor

TdT

terminal deoxynucleotidyltransferase

Th

helper T cells

TNF

tumor necrosis factor

TUNEL

terminal deoxynucleotidyl transferase-mediated dUTP-biotin
nick-labeling

VAF

viral antibody free
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ABSTRACT

Various fungal products have immunomodulating activity and some have been
studied regarding prevention of transplantation rejection. Prior to this investigation, the
mycotoxin, gliotoxin (GT), has never been investigated as an immunotherapeutic drug for

autoimmune disease. GT is a fungal secondary metabolite and a member of the epipolythiodioxopiperazine (ETP) family which has been shown to inhibit phagocytosis, induction

of cytolytic T cells and the proliferation of T cells following mitogen stimulation. GT also

induces in vitro apoptosis in certain immune cell types. More importantly, GT exhibits

selective activity towards cells of hemopoietic origin.
Autoimmune diseases are disorders caused by immune responses to self antigens.

Insulin dependent diabetes mellitus (IDDM) is an organ-specific autoimmune disease in
which insulin secreting pancreatic islet P-cells are destroyed leading to hyperglycemia,

ketoacidosis and various systemic complications. Because of its potential effects on the
immune system, we evaluated GT for its ability to prevent IDDM. This study is the first
to successfully use GT to prevent an autoimmune process.
GT prevented IDDM in spontaneously diabetic DP/BB rats without causing sig

nificant adverse effects among the treated animals. GT treated rats developed diabetes at

a rate of 55% by 120 days of age compared to 90% for control rats. GT treatment also
significantly decreased serum glucose levels from an average 278 mg/dl to 185.67 mg/dl

among non-diabetic/pre-diabetic animals.
A series of studies was conducted on 65 days old DP/BB rats, prior to development of diabetes to phenotypically characterize the splenic lymphocytes recovered from
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animals chronically treated with GT. A parallel study examined the direct effects of GT on
splenocyte preparations incubated with this mycotoxin.

This study found that GT selectively affects certain lymphocyte subsets. Animals
treated with GT showed involution of splenic follicles and several effects on lymphocyte

subpopulations were found. In vitro treatment of splenocytes with GT revealed decreased
CD4" and increased CD8’ T cell subsets. CD8* T cells function as an important regulator

of autoimmunity, especially influencing the activity of CD4+ T cells. GT effects on CD4'
and CD8+ T cells are consistent with changes anticipated to inhibit IDDM pathogenesis.

In vivo treatment with GT did not result in detectable alterations in relative CD4+ and

CD8+ cell subsets, although this may have been more related to pharmacologic reasons
than the physiological effects of GT.

Importantly, this study found that both in vitro and in vivo GT treatments signifi-

cantly enhanced the detectable RT6 surface marker. The RT64 T cell subset is a key
regulatory element in IDDM pathogenesis. Increased numbers of RT6 surface markers

may be involved with IDDM prevention or may be a result of it.
GT induced lymphocyte apoptosis among spleen cells from DP/BB rats was al

tered in vitro. The average increase in apoptotic cells due to GT treatment was nearly

four fold. Results from this study suggested that the mechanism whereby GT prevents
IDDM in DP/BB rats is through apoptosis. Coupled with the finding of altered lympho

cyte populations, it may be suggested that apoptosis of regulatory cells, or effector cells is
involved in diabetes prevention in this system. The finding that CD8* cells and NK cells
which include cytotoxic effectors that can promote pancreatic damage, were not decreased
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by GT treatment suggests that the effects may reside with regulatory cells rather than with

effectors, although additional study is warranted to fully understand this process.
This research is the first to show that GT has a protective effect against an auto

immune disease. We also found that GT is a selective immunomodulator altering the ratio

of CD4+ and CD8+ lymphocytes and causing increased RT6+ surface marker to appear as
an important subset of lymphocytes.

This study is also the first to demonstrate that

apoptosis due to GT treatment occurs in intact animals.
Because indicators of systemic toxicity showed that GT is relatively benign in ex

perimental animals, as evidenced by lack of irreversible histopathology, normal weight
gain and normal leukocyte counts, and it has a beneficial effect on IDDM development,
GT should be considered for continued evaluation as a potential IDDM preventive drug.
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